



Australian Government  
Department of Health and Aged Care

---

# ***Pharmaceutical Benefits Scheme (PBS) Expenditure & Prescriptions Report 1 July 2022 to 30 June 2023***

***PBS Analytics and Strategic Insight Section  
Pricing and PBS Policy Branch  
Technology Assessment and Access Division***

This publication and previous editions can be accessed via the internet:  
<https://www.pbs.gov.au/info/browse/statistics>

Please direct enquiries or feedback to:

Surface mail: Director  
PBS Analytics and Strategic Insight Section  
Pricing and PBS Policy Branch, MDP 900  
Department of Health and Aged Care  
GPO Box 9848 Canberra ACT 2601

E-mail: [pbsstats@health.gov.au](mailto:pbsstats@health.gov.au)

## Important Information

Unless otherwise indicated this publication has been produced using data provided to the Department of Health and Aged Care by Services Australia. The figures reported in this publication relate to the value (benefit) or volume of PBS prescriptions that have been processed by Services Australia. They refer only to paid services processed for prescriptions submitted and claimed via the PBS Online claiming system by approved suppliers. Claims of manually processed PBS programs are excluded.

PBS Expenditure includes the following patient categories:

- General - Non-Safety Net (Ordinary)
- General - Safety Net
- Concessional - Non-Safety Net (Ordinary)
- Concessional - Safety Net
- Doctors' Bag

The financial information in this publication is presented on a cash (expenditure) basis, except where indicated otherwise.

The patient category refers to the patient's eligibility status at the time of supply of the benefit. General patients hold a Medicare card, Concessional patients hold a Medicare card and one of the following cards from Centrelink:

- Pension Concession Card
- Commonwealth Seniors Health Card
- Health Care Card

There are two safety net thresholds – one for General patients and the other for Concessional patients.

From 1 January 2023, the following changes have implemented:

- the general patient safety net threshold was **\$1,563.50**. When patients and/or their families reached this amount, they could apply for a Safety Net Card and pay only **\$7.30** per prescription for the rest of the calendar year. The concessional safety net threshold was **\$262.80**. Once patients and/or their families reached this amount, they could apply for a Safety Net Entitlement Card and receive items free of charge for the rest of the calendar year.
- The PBS general patient co-payment amount was lowered from \$42.50 to **\$30.00** per prescription. The concessional co-payment amount increased from \$6.80 to **\$7.30**.

The Patient Contribution, Total Cost and Average Price amounts do not include brand or therapeutic premiums.

From 2016-17 this publication is based on the date that a prescription medicine was supplied to a patient. Previous publications were based on the date that a claim was processed (and the payment finalised) by Services Australia. The historical data from 1948-49 to 2015-16 in the Excel tables remains by date of processing.

Caution should be exercised in referring to the breakdown by patient category in Table 20(a) and Table 20(b) in the Excel tables, because of a past problem in supply data whereby a number of General Safety Net scripts were wrongly allocated to Concessional Non-Safety Net. This problem was fixed from 2008-09 onwards, but the 2006-07 and 2007-08 allocations of scripts and expenditure by patient category were inaccurate and not strictly comparable to the corresponding 2008-09 and later years' numbers.

While Section 100 data has been included in the majority of tables in this report, this data does not include supplies to Remote Area Aboriginal Health Services with the exception of Tables 1(a) and 1(b) on page 2.

Expenditure on nusinersen and onasemnogene abeparvovec was adjusted to include manual payments that were not processed through the PBS Online system.

The Department of Health and Aged Care has taken every care to ensure the data supplied is accurate but does not warrant that the data is error free and does not accept any liability for errors or omissions in the data.

## Summary of the Pharmaceutical Benefits Scheme 2022-23

Total Pharmaceutical Benefits Scheme (PBS) Government expense for the supply of medicines under Section 85 and Section 100 on an accrual accounting basis for the 2022- 23 financial year was **\$17.0 billion** (excluding revenue), compared with **\$14.7 billion** for the previous year. This is an increase of **15.6%**.

The majority of the Expenditure and Prescriptions report refers to PBS Section 85 and Section 100 data reported by financial year (based on date of supply); however, a few tables refer to Section 85 only and some tables report pharmacy program expenditure.

Total 2022-23 PBS subsidised prescription volume increased by **3.7%** to a total of **223.1 million**, compared to **215.1 million** for the 2021-22 financial year.

In 2022-23, PBS Government expenditure on a cash accounting basis for the supply of medicines under Section 85 and Section 100 was **\$16.7 billion** (excluding rebates) which is **91.4%** of the total cost of PBS prescriptions. The remainder was patient contributions, which amounted to **\$1.6 billion**.

The majority of Government expenditure in 2022-23 on PBS Section 85 and Section 100 prescriptions was directed towards concessional cardholders (**\$10.5 billion, 62.6% of the total**), compared to concessional cardholders' expenditure for 2021-22 (**\$9.3 billion, 64.4% of the total**).

The average dispensed price (Patient payment plus Government benefit) per prescription of PBS subsidised medicines increased to **\$81.73** in 2022-23, compared to **\$74.67** in 2021-22.

There were **928** different medicines in **5,261** brands listed on the PBS as at 30 June 2023.


## Table of content

	Description	Page
<b>Figure 1</b>	Historical PBS Expenditure and Prescription Volume, 2001-02 to 2022-23	<b>1</b>
<b>Table 1(a)</b>	PBS Expense on an Accrual Accounting Basis, 2021-22 and 2022-23	<b>2</b>
<b>Table 1(b)</b>	PBS Section 100 Programs on an Accrual Accounting Basis, 2021-22 and 2022-23	<b>2</b>
<b>Table 2(a)</b>	PBS Prescriptions, 2021-22 and 2022-23	<b>3</b>
<b>Table 2(b)</b>	PBS Government Cost, 2021-22 and 2022-23	<b>3</b>
<b>Table 2(c)</b>	RPBS and PBS Subsidised Prescriptions for DVA patients, 2021-22 and 2022-23	<b>3</b>
<b>Table 2(d)</b>	RPBS and PBS Government Cost for DVA patients, 2021-22 and 2022-23	<b>3</b>
<b>Table 3(a)</b>	PBS Section 85 Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2022-23	<b>4</b>
<b>Table 3(b)</b>	PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2022-23	<b>4</b>
<b>Table 3(c)</b>	PBS Prescriptions, Government Cost, Patient Contribution and Average Price by Month of Supply, 2021-22 and 2022-23	<b>4</b>
<b>Table 4</b>	PBS Subsidised Prescriptions by Pharmacy State, 2022-23	<b>5</b>
<b>Table 5(a)</b>	Top 50 PBS Drugs (by Active Ingredient) Sorted by Highest Government Cost, 2022-23	<b>6</b>
<b>Table 5(b)</b>	Top 50 PBS Drugs (by Active Ingredient) Sorted by Highest Subsidised Prescriptions, 2022-23	<b>7</b>
<b>Table 5(c)</b>	Top 25 PBS Cancer Drugs (by Active Ingredient) Sorted by Highest Government Cost, 2022-23	<b>8</b>
<b>Table 5(d)</b>	Top 25 PBS Biologic Products and Medicines Sorted by Highest Government Cost, 2022-23	<b>8</b>
<b>Table 5(e)</b>	Top 50 PBS Brands Sorted by Highest Government Cost, 2022-23	<b>9</b>
<b>Table 5(f)</b>	Top 50 PBS Brands Sorted by Highest Subsidised Prescriptions, 2022-23	<b>10</b>
<b>Table 5(g)</b>	Biosimilar Products and Medicines (excluding EFC) Sorted by Highest Government Cost, 2022-23	<b>11</b>
<b>Table 6(a)</b>	Top 50 PBS Drugs (by Active Ingredient) Sorted by Highest Total Prescription Volume, 2022-23	<b>12</b>
<b>Table 6(b)</b>	Top 10 PBS Drugs (by Active Ingredient) per age group and patient gender, Sorted by Highest Total Prescription Volume, 2022-23	<b>13</b>
<b>Figure 2</b>	Total PBS Government cost by gender and age-groups in 2022-23	<b>14</b>
<b>Figure 3</b>	Total PBS prescription by gender and age-groups in 2022-23	<b>15</b>
<b>Figure 4</b>	PBS prescriptions dispensed in a Residential Aged Care Facility (RACF), 2022-23	<b>16</b>
<b>Table 6(c)</b>	Top 10 PBS Drugs (Generic Name) sorted by Highest Government Cost, dispensed in a RACF, 2022-23	<b>16</b>
<b>Table 6(d)</b>	Top 10 PBS Drugs (Generic Name) sorted by Highest Prescriptions, dispensed in a RACF, 2022-23	<b>16</b>
<b>Table 7</b>	Top 50 ATC Level 2 Drug Groups Sorted by Highest Total Prescription Volume, 2022-23	<b>17</b>
<b>Table 8</b>	ATC Main Groups Comparison for PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2021-22 and 2022-23	<b>18</b>
<b>Figure 5(a)</b>	Percentages of Subsidised Prescriptions by ATC main groups, 2022-23	<b>19</b>
<b>Figure 5(b)</b>	Percentages of Government Cost by ATC main groups, 2022-23	<b>20</b>
<b>Table 9(a)</b>	Top 35 Drugs Sorted by Highest Change to Government Cost, 2021-22 and 2022-23	<b>21</b>
<b>Table 9(b)</b>	Top 35 Drugs Sorted by Highest Change to Subsidised Prescription Volume, 2021-22 and 2022-23	<b>22</b>
<b>Table 10(a)</b>	PBS Generic Prescriptions and Government Cost per ATC level 1, 2022-23	<b>23</b>
<b>Table 10(b)</b>	PBS Generic Prescriptions and Cost percentages share by ATC level 1, 2022-23	<b>24</b>
<b>Table 11</b>	PBS Prescriptions and Government Cost by Formulary, 2022-23	<b>25</b>
<b>Table 12(a)</b>	Top 20 Responsible Persons by Total Cost, 2022-23	<b>26</b>
<b>Table 12(b)</b>	Top 20 Responsible Persons by PBS Subsidised Prescriptions, 2022-23	<b>27</b>
<b>Table 12(c)</b>	Top 20 Responsible Persons by Total PBS Prescriptions, 2022-23	<b>28</b>
<b>Table 13</b>	Number of PBS Approved Suppliers, 30 June 2023	<b>29</b>
<b>Table 14(a)</b>	PBS Brand Premiums, 2022-23	<b>29</b>
<b>Table 14(b)</b>	Electronic PBS Prescriptions, 2022-23	<b>29</b>
<b>Table 15(a)</b>	PBS/RPBS prescriptions dispensed by Community Pharmacies, 2022-23	<b>30</b>
<b>Table 15(b)</b>	PBS/RPBS prescriptions by Discount Range dispensed by Community Pharmacies, 2022-23	<b>30</b>
<b>Table 16(a)</b>	PBS/RPBS Medicines Supplied under Continued Dispensing by ATC Level 1 and Dispensing Pharmacy State, 2022-23	<b>31</b>
<b>Table 16(b)</b>	PBS/RPBS Continued Dispensing Government Cost by ATC Level 1 and Dispensing Pharmacy State, 2022-23	<b>31</b>

*PBS Expenditure and Prescriptions 2022-23*

<b>Supplement 1</b>	Community Pharmacy Agreement (CPA) Expenses	
<b>Table 17</b>	CPA Professional Pharmacy Programs Expenditure, 2022-23	<b>32</b>
<b>Table 18</b>	Actual Costs of Major Components of CPA, 2022-23	<b>33</b>
<b>Table 19</b>	Community Services Obligation (CSO) Expenditure, 2022-23	<b>33</b>
<b>Supplement 2</b>	PBS Information Line Report, 2022-23	<b>34</b>
<b>Supplement 3</b>	National Diabetes Services Scheme (NDSS)	<b>35</b>

**Figure 1: Historical PBS Expenditure and Prescription Volume, 2001-02 to 2022-23**  
 Section 85 and Section 100 including Doctors' Bag and under co-payment prescriptions\*



\*Amendments to the Commonwealth of Australia National Health Act 1953 was enacted that would require approved suppliers of Pharmaceutical Benefits Scheme (PBS) medicines to provide the Australian Government, from 1 April 2012, with data on PBS prescriptions that are priced below the general copayment level (under copayment). Details of the legislation enacted on 23 November 2010 can be found in the National Health Amendment (Pharmaceutical Benefits Scheme) Act 2010.

PBS Expenditure and Prescriptions 2022-23

Table 1(a): PBS Expense on an Accrual Accounting Basis, 2021-22 and 2022-23

Category	2021-22	Percentage of Total	2022-23	Percentage of Total	Change	Change Percentage
Section 85 - Concessional	\$7,214,557,536	49.2%	\$8,242,967,628	48.5%	\$1,028,410,092	14.3%
Section 85 - General	\$2,877,955,808	19.6%	\$3,675,234,739	21.6%	\$797,278,931	27.7%
Doctor's Bag**	\$15,940,398	0.1%	\$84,059,004	0.5%	\$68,118,606	427.3%
Section 100*	\$4,547,719,795	31.0%	\$4,971,448,827	29.3%	\$423,729,032	9.3%
Safety Net Cards	\$14,478,285	0.1%	\$19,242,896	0.1%	\$4,764,611	32.9%
<b>Total</b>	<b>\$14,670,651,822</b>	<b>100.0%</b>	<b>\$16,992,953,095</b>	<b>100.0%</b>	<b>\$2,322,301,273</b>	<b>15.8%</b>
Total Including Revenue	\$10,924,747,250		\$12,341,307,185		\$1,416,559,935	13.0%

\*Individual S100 programs are shown in Table 1(b).

\*\*In 2022-23 dispensing of COVID-19 therapies MOLNUPIRAVIR and NIRMATRELVIR (&) RITONAVIR through doctor's bag cost the government over \$60m

Table 1(b): PBS Section 100 Programs on an Accrual Accounting Basis, 2021-22 and 2022-23

Category	2021-22	Percentage of Total	2022-23	Percentage of Total	Change	Change Percentage
Highly Specialised Medicines	\$2,156,466,697	47.4%	\$2,441,943,534	49.1%	\$285,476,837	13.2%
Chemotherapy (EFC & Chemotherapy-related)	\$1,906,534,154	41.9%	\$1,999,231,593	40.2%	\$92,697,439	4.9%
In Vitro Fertilisation	\$151,496,719	3.3%	\$161,479,146	3.2%	\$9,982,427	6.6%
Opiate Dependence Treatment Program*	\$108,372,517	2.4%	\$133,907,727	2.7%	\$25,535,210	23.6%
Aboriginal Health Services (GST exclusive)	\$54,529,630	1.2%	\$65,568,912	1.3%	\$11,039,283	20.2%
Botulinum Toxin Program (incl. Dysport)	\$67,378,254	1.5%	\$70,081,895	1.4%	\$2,703,640	4.0%
Growth Hormone	\$35,601,253	0.8%	\$35,403,949	0.7%	-\$197,304	-0.6%
Paraplegic and Quadriplegic Program	\$172,655	0.0%	\$127,939	0.0%	-\$44,716	-25.9%
Medication Program for Homeless People	\$120,863	0.0%	\$131,752	0.0%	\$10,890	9.0%
Closing the Gap (CTG) PBS Co-payment Program	\$67,047,055	1.5%	\$63,572,381	1.3%	-\$3,474,674	-5.2%
<b>Total</b>	<b>\$4,547,719,795</b>	<b>100.0%</b>	<b>\$4,971,448,827</b>	<b>100.0%</b>	<b>\$423,729,032</b>	<b>9.3%</b>

Note:

Expense figures refer to payments made through the Services Australia and directly from the Department of Health and Aged Care Financial Journaling System.

This data reflects the current definitions of Section 100 programs as published on [www.pbs.gov.au](http://www.pbs.gov.au).

\* There has been an increase in ODTP expenditure since the listing of long-acting injectable buprenorphine injection formulations in 2019. 2022-23 shows a continuation in increase although smaller than seen in 2021-22.

**PBS Expenditure and Prescriptions 2022-23**

**Table 2(a): PBS Prescriptions, 2021-22 and 2022-23**

Section 85 and S100, including Doctors' Bag and under co-payment prescriptions

Patient Category	2021-22		2022-23		PBS Prescriptions Change	PBS Prescriptions Change Percentage
	PBS Prescriptions	Percentage	PBS Prescriptions	Percentage		
Concessional Non-Safety Net	143,715,028	66.8%	127,909,160	57.3%	-15,805,868	-11.0%
Concessional Safety Net	50,585,126	23.5%	70,568,682	31.6%	19,983,556	39.5%
<b>Total Concessional</b>	<b>194,300,154</b>	<b>90.3%</b>	<b>198,477,842</b>	<b>89.0%</b>	<b>4,177,688</b>	<b>2.2%</b>
General Non-Safety Net	17,552,265	8.2%	21,024,041	9.4%	3,471,776	19.8%
General Safety Net	2,877,928	1.3%	3,225,102	1.4%	347,174	12.1%
<b>Total General</b>	<b>20,430,193</b>	<b>9.5%</b>	<b>24,249,143</b>	<b>10.9%</b>	<b>3,818,950</b>	<b>18.7%</b>
Doctors Bag	355,495	0.2%	382,691	0.2%	27,196	7.7%
<b>Total (Over Co-payment)</b>	<b>215,085,842</b>	<b>100.0%</b>	<b>223,109,676</b>	<b>100.0%</b>	<b>8,023,834</b>	<b>3.7%</b>
Under Co-payment	100,798,462		105,611,439		4,812,977	4.8%
<b>Total (Over and Under Co-payment)</b>	<b>315,884,304</b>		<b>328,721,115</b>		<b>12,836,811</b>	<b>4.1%</b>

**Table 2(b): PBS Government Cost, 2021-22 and 2022-23**

Section 85 and S100, including Doctors' Bag and excluding under co-payment prescriptions.

Patient Category	2021-22		2022-23		Government Cost Change	Government Cost Change Percentage
	Government Cost	Percentage	Government Cost	Percentage		
Concessional Non-Safety Net	\$7,267,267,771	50.3%	\$7,353,305,517	44.0%	\$86,037,746	1.2%
Concessional Safety Net	\$2,035,731,265	14.1%	\$3,115,587,529	18.6%	\$1,079,856,264	53.0%
<b>Total Concessional</b>	<b>\$9,302,999,036</b>	<b>64.4%</b>	<b>\$10,468,893,046</b>	<b>62.6%</b>	<b>\$1,165,894,010</b>	<b>12.5%</b>
General Non-Safety Net	\$4,978,582,346	34.4%	\$5,975,911,615	35.8%	\$997,329,269	20.0%
General Safety Net	\$156,470,487	1.1%	\$193,530,426	1.2%	\$37,059,940	23.7%
<b>Total General</b>	<b>\$5,135,052,833</b>	<b>35.5%</b>	<b>\$6,169,442,041</b>	<b>36.9%</b>	<b>\$1,034,389,208</b>	<b>20.1%</b>
Doctors Bag*	\$14,229,382	0.1%	\$75,847,810	0.5%	\$61,618,427	433.0%
<b>Total (Over Co-payment)</b>	<b>\$14,452,281,252</b>	<b>100.0%</b>	<b>\$16,714,182,897</b>	<b>100.0%</b>	<b>\$2,261,901,645</b>	<b>15.7%</b>

\*In 2022-23 dispensing of COVID-19 therapies MOLNUIPIRAVIR and NIRMATRELVIR (&) RITONAVIR through doctor's bag cost the government over \$60m

**Table 2(c): RPBS and PBS Subsidised Prescriptions for DVA patients, 2021-22 and 2022-23**

PBS Section 85 and S100 and RPBS items for DVA patients, excluding under co-payment prescriptions.

Patient Category	2021-22		2022-23		Subsidised Prescriptions Change	Subsidised Prescriptions Change Percentage
	Subsidised Prescriptions	Percentage	Subsidised Prescriptions	Percentage		
Repatriation Non-Safety Net	4,892,996	67.3%	4,094,923	57.7%	-798,073	-16.3%
Repatriation Safety Net	2,373,876	32.7%	3,000,664	42.3%	626,788	26.4%
<b>Total Repatriation</b>	<b>7,266,872</b>	<b>100.0%</b>	<b>7,095,587</b>	<b>100%</b>	<b>-171,285</b>	<b>-2.4%</b>

**Table 2(d): RPBS and PBS Government Cost for DVA patients, 2021-22 and 2022-23**

PBS Section 85 and S100 and RPBS items for DVA patients, excluding under co-payment prescriptions.

Patient Category	2021-22		2022-23		Government Cost Change	Government Cost Change Percentage
	Government Cost	Percentage	Government Cost	Percentage		
Repatriation Non-Safety Net	\$246,066,567	73.1%	\$241,097,105	65.6%	-\$4,969,461	-2.0%
Repatriation Safety Net	\$90,439,342	26.9%	\$126,656,107	34.4%	\$36,216,765	40.0%
<b>Total Repatriation</b>	<b>\$336,505,909</b>	<b>100.0%</b>	<b>\$367,753,212</b>	<b>100.0%</b>	<b>\$31,247,304</b>	<b>9.3%</b>

The figures in tables 2(c) and 2(d) will be different than figures currently published in the DVA Annual Report, as expenditure changes due to allowable pharmacy claim adjustments, and processing of historical or delayed claiming by providers.

PBS Expenditure and Prescriptions 2022-23

**Table 3(a): PBS Section 85 Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2022-23**  
Section 85 only, including Doctor's Bag, excluding under co-payment prescriptions.

Patient Category	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
Concessional Non-Safety Net	126,509,960	\$5,146,443,590	\$867,856,016	\$6,014,299,606	\$47.54
Concessional Safety Net	70,299,122	\$2,822,505,250	\$0	\$2,822,505,250	\$40.15
<b>Total Concessional</b>	<b>196,809,082</b>	<b>\$7,968,948,840</b>	<b>\$867,856,016</b>	<b>\$8,836,804,856</b>	<b>\$44.90</b>
General Non-Safety Net	19,253,230	\$3,434,664,506	\$621,265,989	\$4,055,930,496	\$210.66
General Safety Net	3,195,796	\$159,891,298	\$21,016,479	\$180,907,777	\$56.61
<b>Total General</b>	<b>22,449,026</b>	<b>\$3,594,555,804</b>	<b>\$642,282,468</b>	<b>\$4,236,838,272</b>	<b>\$188.73</b>
<b>Total (excluding Drs Bag)</b>	<b>219,258,108</b>	<b>\$11,563,504,644</b>	<b>\$1,510,138,484</b>	<b>\$13,073,643,129</b>	<b>\$59.63</b>
Doctors Bag	382,691	\$75,847,810	\$0	\$75,847,810	\$198.20
<b>Total (including Drs Bag)</b>	<b>219,640,799</b>	<b>\$11,639,352,454</b>	<b>\$1,510,138,484</b>	<b>\$13,149,490,938</b>	<b>\$59.87</b>

\* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

\*\* Average Price is Total Cost divided by PBS Subsidised Prescriptions.

\*\*\* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

**Table 3(b): PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2022-23**  
Section 85 and Section 100, including Doctor's Bag, excluding under co-payment prescriptions.

Patient Category	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
Concessional Non-Safety Net	127,909,160	\$7,353,305,517	\$874,772,300	\$8,228,077,817	\$64.33
Concessional Safety Net	70,568,682	\$3,115,587,529	\$0	\$3,115,587,529	\$44.15
<b>Total Concessional</b>	<b>198,477,842</b>	<b>\$10,468,893,046</b>	<b>\$874,772,300</b>	<b>\$11,343,665,346</b>	<b>\$57.15</b>
General Non-Safety Net	21,024,041	\$5,975,911,615	\$668,323,272	\$6,644,234,887	\$316.03
General Safety Net	3,225,102	\$193,530,426	\$21,178,394	\$214,708,821	\$66.57
<b>Total General</b>	<b>24,249,143</b>	<b>\$6,169,442,041</b>	<b>\$689,501,666</b>	<b>\$6,858,943,707</b>	<b>\$282.85</b>
<b>Total (excluding Drs Bag)</b>	<b>222,726,985</b>	<b>\$16,638,335,087</b>	<b>\$1,564,273,966</b>	<b>\$18,202,609,053</b>	<b>\$81.73</b>
Doctors Bag	382,691	\$75,847,810	\$0	\$75,847,810	\$198.20
<b>Total (including Drs Bag)</b>	<b>223,109,676</b>	<b>\$16,714,182,897</b>	<b>\$1,564,273,966</b>	<b>\$18,278,456,863</b>	<b>\$81.93</b>

\* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

\*\* Average Price is Total Cost divided by PBS Subsidised Prescriptions.

\*\*\* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

**Table 3(c): PBS Prescriptions, Government Cost, Patient Contribution and Average Price by Month of Supply, 2021-22 and 2022-23**  
Section 85 and Section 100, excluding Doctors' Bag and including under co-payment prescriptions.

Year	Month	PBS Subsidised Prescriptions	Under Co-Payment Prescriptions	Total Prescriptions	Government Cost	Patient Contribution (Subsidised Prescriptions only) ***	Total Cost*	Ave. Price**
2021	Jul	18,282,735	8,570,156	26,852,891	\$1,177,707,793	\$131,289,261	\$1,308,997,054	\$71.60
	Aug	18,364,003	8,480,755	26,844,758	\$1,213,359,482	\$123,271,520	\$1,336,631,002	\$72.79
	Sep	18,130,684	8,018,293	26,148,977	\$1,214,371,855	\$113,130,210	\$1,327,502,064	\$73.22
	Oct	18,179,081	7,975,574	26,154,655	\$1,188,872,431	\$107,671,141	\$1,296,543,572	\$71.32
	Nov	19,005,939	8,010,997	27,016,936	\$1,277,603,851	\$105,651,921	\$1,383,255,772	\$72.78
	Dec	21,158,154	8,177,150	29,335,304	\$1,350,254,399	\$104,853,262	\$1,455,107,660	\$68.77
2022	Jan	15,273,002	8,092,332	23,365,334	\$1,037,895,170	\$143,306,342	\$1,181,201,512	\$77.34
	Feb	15,580,166	7,767,750	23,347,916	\$1,059,833,154	\$144,574,266	\$1,204,407,420	\$77.30
	Mar	18,029,108	8,958,941	26,988,049	\$1,237,126,283	\$165,899,408	\$1,403,025,691	\$77.82
	Apr	16,753,981	8,430,851	25,184,832	\$1,129,503,098	\$150,908,269	\$1,280,411,367	\$76.42
	May	18,042,127	9,204,864	27,246,991	\$1,269,214,872	\$156,212,125	\$1,425,426,997	\$79.01
	Jun	17,931,367	9,110,783	27,042,150	\$1,282,309,482	\$146,084,573	\$1,428,394,055	\$79.66
<b>Total</b>		<b>214,730,347</b>	<b>100,798,446</b>	<b>315,528,793</b>	<b>\$14,438,051,869</b>	<b>\$1,592,852,297</b>	<b>\$16,030,904,166</b>	<b>\$74.66</b>
2022	Jul	18,138,898	9,104,359	27,243,257	\$1,372,988,784	\$125,281,468	\$1,498,270,252	\$82.60
	Aug	19,330,098	9,370,107	28,700,205	\$1,445,342,436	\$121,692,759	\$1,567,035,195	\$81.07
	Sep	18,596,334	8,830,643	27,426,977	\$1,359,863,750	\$108,513,594	\$1,468,377,344	\$78.96
	Oct	18,832,525	8,797,286	27,629,811	\$1,338,502,188	\$103,342,701	\$1,441,844,889	\$76.56
	Nov	19,678,831	8,681,317	28,360,148	\$1,534,948,773	\$102,928,336	\$1,637,877,109	\$83.23
	Dec	21,871,469	8,611,487	30,482,956	\$1,632,777,559	\$100,313,425	\$1,733,090,984	\$79.24
2023	Jan	15,866,548	8,231,471	24,098,019	\$1,247,597,033	\$148,516,645	\$1,396,113,678	\$87.99
	Feb	16,267,971	8,018,785	24,286,756	\$1,206,596,207	\$150,962,487	\$1,357,558,693	\$83.45
	Mar	18,835,018	9,076,487	27,911,505	\$1,431,514,598	\$170,934,693	\$1,602,449,291	\$85.08
	Apr	17,033,761	8,456,932	25,490,693	\$1,209,811,793	\$145,524,777	\$1,355,336,570	\$79.57
	May	19,576,290	9,388,262	28,964,552	\$1,479,792,226	\$153,354,123	\$1,633,146,348	\$83.42
	Jun	18,699,242	9,044,303	27,743,545	\$1,378,599,740	\$132,908,959	\$1,511,508,700	\$80.83
<b>Total</b>		<b>222,726,985</b>	<b>105,611,439</b>	<b>328,338,424</b>	<b>\$16,638,335,087</b>	<b>\$1,564,273,966</b>	<b>\$18,202,609,053</b>	<b>\$81.73</b>

\* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

\*\* Average Price is Total Cost divided by PBS Subsidised Prescriptions.

\*\*\* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

PBS Expenditure and Prescriptions 2022-23

**Table 4: PBS Subsidised Prescriptions by Pharmacy State, 2022-23**

Section 85 and Section 100, excluding Doctors' Bag and excluding under co-payment prescriptions

PBS S85 subsidised prescriptions	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	40,172,019	31,437,589	26,759,785	10,675,889	11,941,668	3,646,078	518,644	1,358,288	126,509,960
Concessional Safety Net	23,238,482	17,330,458	14,544,095	5,914,407	6,291,899	2,108,155	149,739	721,887	70,299,122
General Non-Safety Net	6,169,449	4,626,004	3,999,014	1,224,547	2,179,778	445,809	176,663	431,966	19,253,230
General Safety Net	1,079,918	782,672	581,625	210,642	368,083	68,330	10,246	94,280	3,195,796
<b>Total</b>	<b>70,659,868</b>	<b>54,176,723</b>	<b>45,884,519</b>	<b>18,025,485</b>	<b>20,781,428</b>	<b>6,268,372</b>	<b>855,292</b>	<b>2,606,421</b>	<b>219,258,108</b>
PBS (S85 + S100) subsidised prescriptions	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	40,596,883	31,782,058	27,061,838	10,789,058	12,076,423	3,682,042	531,139	1,389,719	127,909,160
Concessional Safety Net	23,316,649	17,407,069	14,600,541	5,935,873	6,317,119	2,115,345	150,762	725,324	70,568,682
General Non-Safety Net	6,754,380	5,077,946	4,313,651	1,334,269	2,365,537	473,536	192,379	512,343	21,024,041
General Safety Net	1,086,587	793,481	588,155	211,999	371,078	68,688	10,300	94,814	3,225,102
<b>Total</b>	<b>71,754,499</b>	<b>55,060,554</b>	<b>46,564,185</b>	<b>18,271,199</b>	<b>21,130,157</b>	<b>6,339,611</b>	<b>884,580</b>	<b>2,722,200</b>	<b>222,726,985</b>
Government Cost (S85 only)	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	\$1,683,170,278	\$1,256,196,782	\$1,058,199,912	\$431,052,167	\$491,206,734	\$149,506,447	\$19,344,389	\$57,766,880	\$5,146,443,590
Concessional Safety Net	\$924,775,653	\$701,825,760	\$564,496,486	\$241,326,119	\$263,973,901	\$89,059,840	\$5,163,931	\$31,883,559	\$2,822,505,250
General Non-Safety Net	\$1,123,884,922	\$910,328,916	\$620,691,072	\$233,596,360	\$365,886,537	\$83,160,467	\$23,019,773	\$74,096,460	\$3,434,664,506
General Safety Net	\$53,825,310	\$40,812,450	\$26,913,207	\$10,464,469	\$18,806,268	\$3,619,478	\$509,487	\$4,940,630	\$159,891,298
<b>Total</b>	<b>\$3,785,656,163</b>	<b>\$2,909,163,908</b>	<b>\$2,270,300,676</b>	<b>\$916,439,116</b>	<b>\$1,139,873,441</b>	<b>\$325,346,232</b>	<b>\$48,037,579</b>	<b>\$168,687,530</b>	<b>\$11,563,504,644</b>
Government Cost (S85 + S100)	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	\$2,350,407,764	\$1,772,955,864	\$1,588,182,181	\$608,161,712	\$703,482,026	\$213,237,447	\$30,546,106	\$86,332,417	\$7,353,305,517
Concessional Safety Net	\$995,062,098	\$780,967,598	\$636,997,927	\$271,796,929	\$291,261,326	\$99,205,496	\$5,814,671	\$34,481,484	\$3,115,587,529
General Non-Safety Net	\$1,959,413,498	\$1,531,093,215	\$1,127,137,132	\$385,473,079	\$662,460,661	\$123,230,206	\$41,956,416	\$145,147,408	\$5,975,911,615
General Safety Net	\$60,653,905	\$52,373,113	\$34,487,570	\$12,399,417	\$23,170,086	\$4,227,304	\$560,958	\$5,658,073	\$193,530,426
<b>Total</b>	<b>\$5,365,537,266</b>	<b>\$4,137,389,790</b>	<b>\$3,386,804,810</b>	<b>\$1,277,831,137</b>	<b>\$1,680,374,098</b>	<b>\$439,900,453</b>	<b>\$78,878,151</b>	<b>\$271,619,382</b>	<b>\$16,638,335,087</b>
Total Cost (S85 + S100)*	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	\$2,626,164,476	\$1,996,028,650	\$1,770,186,220	\$682,543,233	\$785,615,119	\$238,178,863	\$33,365,210	\$95,996,046	\$8,228,077,817
Concessional Safety Net	\$995,062,098	\$780,967,598	\$636,997,927	\$271,796,929	\$291,261,326	\$99,205,496	\$5,814,671	\$34,481,484	\$3,115,587,529
General Non-Safety Net	\$2,169,888,954	\$1,702,825,034	\$1,258,130,569	\$428,493,350	\$738,272,272	\$137,539,966	\$46,619,902	\$162,464,839	\$6,644,234,887
General Safety Net	\$67,742,684	\$57,707,963	\$38,264,600	\$13,802,589	\$25,617,234	\$4,664,243	\$617,074	\$6,292,433	\$214,708,821
<b>Total</b>	<b>\$5,858,858,213</b>	<b>\$4,537,529,246</b>	<b>\$3,703,579,316</b>	<b>\$1,396,636,102</b>	<b>\$1,840,765,951</b>	<b>\$479,588,569</b>	<b>\$86,416,856</b>	<b>\$299,234,801</b>	<b>\$18,202,609,053</b>
Population Percentage	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Population**	8,238,801	6,704,281	5,378,277	1,834,275	2,825,178	571,596	250,149	460,855	26,268,359
PBS S85 Subsidised Scripts per Capita	8.58	8.08	8.53	9.83	7.36	10.97	3.42	5.66	8.35
PBS (S85 + S100) Subsidised Scripts per Capita	8.71	8.21	8.66	9.96	7.48	11.09	3.54	5.91	8.48
PBS S85 Govt Cost per Capita	\$459.49	\$433.93	\$422.12	\$499.62	\$403.47	\$569.19	\$192.04	\$366.03	\$440.21
PBS (S85 + S100) Govt Cost per Capita	\$651.25	\$617.13	\$629.72	\$696.64	\$594.79	\$769.60	\$315.32	\$589.38	\$633.40
Population Percentage	31.36%	25.52%	20.47%	6.98%	10.76%	2.18%	0.95%	1.75%	100.00%
PBS (S85 + S100) Subsidised Scripts Percentage	32.22%	24.72%	20.91%	8.20%	9.49%	2.85%	0.40%	1.22%	100.00%
PBS (S85 + S100) Govt Cost Percentage	32.25%	24.87%	20.36%	7.68%	10.10%	2.64%	0.47%	1.63%	100.00%
Total Cost Percentage	32.19%	24.93%	20.35%	7.67%	10.11%	2.63%	0.47%	1.64%	100.00%

\* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions (S85 + S100 prescriptions).

\*\*Population 31 December 2022, Source: ABS Publication 3101.04

**Table 5(a): Top 50 PBS Medicines (by Active Ingredient) Sorted by Highest Government Cost, 2022-23**  
 Section 85 and Section 100, including Doctors' Bag, excluding under co-payment prescriptions.

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
1	MOLNUPIRAVIR	581,630	\$646,447,181	\$7,983,553	\$654,430,734	\$1,125.17
2	ELEXACAFTOR + TEZACAFTOR + IVACAFTOR (& IVACAFTOR	24,008	\$512,857,553	\$377,478	\$513,235,031	\$21,377.67
3	AFLIBERCEPT	443,012	\$476,143,532	\$6,399,432	\$482,542,964	\$1,089.23
4	PEMBROLIZUMAB	52,663	\$447,023,724	\$227,317	\$447,251,041	\$8,492.70
5	NIVOLUMAB	56,066	\$411,450,540	\$246,197	\$411,696,738	\$7,343.07
6	USTEKINUMAB	48,857	\$355,959,026	\$1,300,262	\$357,259,288	\$7,312.35
7	NIRMATRELVIR (&) RITONAVIR	290,916	\$334,491,173	\$4,903,076	\$339,394,249	\$1,166.64
8	APIXABAN	3,717,593	\$304,367,581	\$39,406,767	\$343,774,347	\$92.47
9	ADALIMUMAB	330,586	\$282,747,367	\$8,209,063	\$290,956,430	\$880.12
10	DENOSUMAB	1,083,960	\$272,776,093	\$11,636,712	\$284,412,805	\$262.38
11	DUPILUMAB	151,157	\$258,822,624	\$4,020,461	\$262,843,085	\$1,738.87
12	OCRELIZUMAB	12,437	\$212,469,344	\$370,636	\$212,839,979	\$17,113.45
13	LENALIDOMIDE	45,526	\$181,261,532	\$824,084	\$182,085,616	\$3,999.60
14	UPADACITINIB	122,466	\$158,312,784	\$2,705,066	\$161,017,850	\$1,314.80
15	RANIBIZUMAB	141,510	\$154,853,506	\$1,842,286	\$156,695,792	\$1,107.31
16	IPILIMUMAB	7,463	\$151,019,563	\$63,743	\$151,083,307	\$20,244.31
17	GLECAPREVIR + PIBRENTASVIR	8,375	\$148,827,628	\$212,500	\$149,040,128	\$17,795.84
18	SOFOSBUVIR + VELPATASVIR	11,846	\$147,255,752	\$247,283	\$147,503,035	\$12,451.72
19	SEMAGLUTIDE	1,255,370	\$146,166,023	\$20,910,340	\$167,076,364	\$133.09
20	OSIMERTINIB	18,403	\$146,147,284	\$330,734	\$146,478,018	\$7,959.46
21	RIVAROXABAN	2,572,037	\$138,099,176	\$31,799,460	\$169,898,636	\$66.06
22	ATEZOLIZUMAB	18,350	\$136,087,685	\$98,320	\$136,186,005	\$7,421.58
23	DARATUMUMAB	18,759	\$135,322,802	\$258,398	\$135,581,200	\$7,227.53
24	FERRIC CARBOXYMALTOS	498,481	\$132,181,193	\$12,338,555	\$144,519,748	\$289.92
25	VEDOLIZUMAB	52,249	\$130,758,629	\$1,518,153	\$132,276,782	\$2,531.66
26	GUSELUMAB	33,022	\$124,482,254	\$869,788	\$125,352,042	\$3,796.02
27	SACUBITRIL + VALSARTAN	661,338	\$120,538,619	\$7,815,757	\$128,354,376	\$194.08
28	ENZALUTAMIDE	34,068	\$119,709,202	\$365,786	\$120,074,988	\$3,524.57
29	BICTEGRAVIR + EMTRICITABINE + TENOFOVIR ALAFENAMIDE	62,275	\$109,721,416	\$1,655,115	\$111,376,531	\$1,788.46
30	IBRUTINIB	11,967	\$108,391,122	\$147,594	\$108,538,717	\$9,069.84
31	ROSUVASTATIN	9,708,579	\$107,245,624	\$46,771,590	\$154,017,215	\$15.86
32	ETANERCEPT	104,690	\$103,228,102	\$2,094,179	\$105,322,281	\$1,006.04
33	INFLIXIMAB	87,787	\$95,979,389	\$2,622,948	\$98,602,337	\$1,123.20
34	SECUKINUMAB	68,220	\$93,886,065	\$1,672,110	\$95,558,174	\$1,400.74
35	PALBOCICLIB	22,193	\$93,534,741	\$344,834	\$93,879,575	\$4,230.14
36	ATORVASTATIN	8,095,183	\$88,233,130	\$37,229,314	\$125,462,445	\$15.50
37	LISDEXAMFETAMINE	1,173,716	\$86,094,302	\$29,805,831	\$115,900,133	\$98.75
38	GOLIMUMAB	74,841	\$84,989,722	\$1,818,006	\$86,807,728	\$1,159.90
39	DARBEPOETIN ALFA	80,104	\$84,523,734	\$1,049,035	\$85,572,769	\$1,068.27
40	CLADRIBINE	4,786	\$80,299,617	\$116,349	\$80,415,967	\$16,802.33
41	RIBOCICLIB	17,600	\$79,825,379	\$310,221	\$80,135,600	\$4,553.16
42	PALIPERIDONE	239,638	\$79,074,288	\$2,391,940	\$81,466,228	\$339.96
43	RUXOLITINIB	16,793	\$77,953,617	\$230,818	\$78,184,435	\$4,655.78
44	VENETOCLAX	11,728	\$75,764,341	\$169,341	\$75,933,683	\$6,474.56
45	BUDESONIDE + FORMOTEROL	2,234,152	\$75,341,804	\$42,089,925	\$117,431,729	\$52.56
46	PANTOPRAZOLE	6,950,228	\$74,501,454	\$30,764,122	\$105,265,576	\$15.15
47	RISANKIZUMAB	13,779	\$73,972,197	\$378,351	\$74,350,548	\$5,395.93
48	ESOMEPRAZOLE	5,658,543	\$73,452,010	\$25,207,965	\$98,659,975	\$17.44
49	DURVALUMAB	8,896	\$71,410,842	\$38,179	\$71,449,022	\$8,031.59
50	FLUTICASONE PROPIONATE + SALMETEROL	1,911,651	\$69,731,224	\$32,703,358	\$102,434,582	\$53.58

\* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

\*\* Average Price is Total Cost divided by PBS Subsidised Prescriptions.

\*\*\* The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

**Table 5(b): Top 50 PBS Medicines (by Active Ingredient) Sorted by Highest Subsidised Prescriptions, 2022-23**  
 Section 85 and Section 100, including Doctors' Bag, excluding under co-payment prescriptions.

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
1	ROSUVASTATIN	9,708,579	\$107,245,624	\$46,771,590	\$154,017,215	\$15.86
2	ATORVASTATIN	8,095,183	\$88,233,130	\$37,229,314	\$125,462,445	\$15.50
3	PANTOPRAZOLE	6,950,228	\$74,501,454	\$30,764,122	\$105,265,576	\$15.15
4	ESOMEPRAZOLE	5,658,543	\$73,452,010	\$25,207,965	\$98,659,975	\$17.44
5	PERINDOPRIL	4,189,988	\$45,709,385	\$20,322,206	\$66,031,591	\$15.76
6	APIXABAN	3,717,593	\$304,367,581	\$39,406,767	\$343,774,347	\$92.47
7	METFORMIN	3,667,491	\$44,880,772	\$14,966,583	\$59,847,354	\$16.32
8	AMLODIPINE	3,208,697	\$32,297,058	\$14,736,064	\$47,033,122	\$14.66
9	PREGABALIN	3,025,457	\$52,759,038	\$11,793,267	\$64,552,305	\$21.34
10	SALBUTAMOL	2,821,377	\$52,375,271	\$10,893,912	\$63,269,183	\$22.42
11	IRBESARTAN	2,650,655	\$27,998,493	\$12,484,090	\$40,482,583	\$15.27
12	TELMISARTAN	2,577,298	\$27,400,232	\$12,867,683	\$40,267,915	\$15.62
13	RIVAROXABAN	2,572,037	\$138,099,176	\$31,799,460	\$169,898,636	\$66.06
14	CANDESARTAN	2,502,137	\$26,806,426	\$12,223,542	\$39,029,968	\$15.60
15	SERTRALINE	2,447,807	\$25,578,323	\$12,396,600	\$37,974,923	\$15.51
16	ESCITALOPRAM	2,412,389	\$24,763,248	\$12,468,802	\$37,232,051	\$15.43
17	MIRTAZAPINE	2,344,566	\$27,912,105	\$10,313,089	\$38,225,194	\$16.30
18	CEFALEXIN	2,330,170	\$24,117,494	\$11,913,408	\$36,030,901	\$15.46
19	BUDESONIDE + FORMOTEROL	2,234,152	\$75,341,804	\$42,089,925	\$117,431,729	\$52.56
20	RAMIPRIL	2,086,955	\$22,170,964	\$9,578,463	\$31,749,427	\$15.21
21	ATENOLOL	1,977,502	\$21,374,353	\$8,750,533	\$30,124,886	\$15.23
22	OXYCODONE	1,971,434	\$47,983,175	\$10,032,856	\$58,016,031	\$29.43
23	FLUTICASONE PROPIONATE + SALMETEROL	1,911,651	\$69,731,224	\$32,703,358	\$102,434,582	\$53.58
24	METOPROLOL TARTRATE	1,885,583	\$20,250,076	\$7,684,061	\$27,934,136	\$14.81
25	PARACETAMOL + CODEINE	1,852,937	\$39,062,219	\$9,832,477	\$48,894,696	\$26.39
26	VENLAFAXINE	1,832,293	\$22,703,783	\$9,037,191	\$31,740,974	\$17.32
27	CLOPIDOGREL	1,816,990	\$22,402,242	\$7,155,598	\$29,557,839	\$16.27
28	AMITRIPTYLINE	1,771,636	\$20,319,158	\$7,553,363	\$27,872,521	\$15.73
29	BISOPROLOL	1,740,737	\$25,988,612	\$7,272,533	\$33,261,145	\$19.11
30	PARACETAMOL	1,740,300	\$26,762,155	\$5,709,842	\$32,471,997	\$18.66
31	DUTASTERIDE + TAMSULOSIN	1,734,703	\$41,696,359	\$10,237,769	\$51,934,128	\$29.94
32	LERCANIDIPINE	1,726,399	\$19,323,789	\$7,415,711	\$26,739,500	\$15.49
33	AMOXICILLIN	1,715,435	\$17,335,998	\$9,516,795	\$26,852,794	\$15.65
34	RABEPRAZOLE	1,682,516	\$18,778,882	\$7,496,542	\$26,275,424	\$15.62
35	PERINDOPRIL + AMLODIPINE	1,669,057	\$19,992,783	\$8,773,548	\$28,766,331	\$17.24
36	SIMVASTATIN	1,508,765	\$15,831,340	\$6,731,000	\$22,562,340	\$14.95
37	SITAGLIPTIN + METFORMIN	1,501,279	\$46,513,682	\$21,853,935	\$68,367,617	\$45.54
38	FUROSEMIDE	1,474,496	\$17,286,308	\$5,321,317	\$22,607,625	\$15.33
39	EMPAGLIFLOZIN	1,460,842	\$67,934,756	\$19,815,779	\$87,750,534	\$60.07
40	DIAZEPAM	1,369,445	\$12,910,759	\$6,396,615	\$19,307,374	\$14.10
41	GLICLAZIDE	1,362,439	\$20,356,535	\$4,992,109	\$25,348,644	\$18.61
42	AMOXICILLIN + CLAVULANIC ACID	1,357,200	\$15,651,602	\$7,077,825	\$22,729,426	\$16.75
43	PREDNISOLONE	1,343,151	\$14,835,836	\$5,818,172	\$20,654,007	\$15.38
44	MELOXICAM	1,334,892	\$15,089,125	\$6,295,939	\$21,385,065	\$16.02
45	IRBESARTAN + HYDROCHLOROTHIAZIDE	1,333,321	\$14,821,644	\$6,382,249	\$21,203,893	\$15.90
46	DULOXETINE	1,295,933	\$18,034,985	\$5,934,277	\$23,969,261	\$18.50
47	SEMAGLUTIDE	1,255,370	\$146,166,023	\$20,910,340	\$167,076,364	\$133.09
48	MACROGOL-3350 + SODIUM CHLORIDE + BICARBONATE + POTASSIUM CHLORIDE	1,228,954	\$20,490,353	\$4,564,018	\$25,054,370	\$20.39
49	OXYCODONE + NALOXONE	1,215,844	\$48,548,355	\$8,675,181	\$57,223,536	\$47.06
50	DESVENLAFAXINE	1,214,605	\$22,700,663	\$7,957,894	\$30,658,557	\$25.24

\* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

\*\* Average Price is Total Cost divided by PBS Subsidised Prescriptions.

\*\*\* The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

**Table 5(c): Top 25 PBS Antineoplastic Drugs (by Active Ingredient) Sorted by Highest Government Cost, 2022-23**  
Section 85 and Section 100, excluding under co-payment prescriptions.

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
1	PEMBROLIZUMAB	52,663	\$447,023,724	\$227,317	\$447,251,041	\$8,492.70
2	NIVOLUMAB	56,066	\$411,450,540	\$246,197	\$411,696,738	\$7,343.07
3	LENALIDOMIDE	45,526	\$181,261,532	\$824,084	\$182,085,616	\$3,999.60
4	IPILIMUMAB	7,463	\$151,019,563	\$63,743	\$151,083,307	\$20,244.31
5	OSIMERTINIB	18,403	\$146,147,284	\$330,734	\$146,478,018	\$7,959.46
6	ATEZOLIZUMAB	18,350	\$136,087,685	\$98,320	\$136,186,005	\$7,421.58
7	DARATUMUMAB^^	17,603	\$127,108,345	\$238,900	\$127,347,245	\$7,234.41
8	ENZALUTAMIDE	34,068	\$119,709,202	\$365,786	\$120,074,988	\$3,524.57
9	IBRUTINIB	11,967	\$108,391,122	\$147,594	\$108,538,717	\$9,069.84
10	PALBOCICLIB	22,193	\$93,534,741	\$344,834	\$93,879,575	\$4,230.14
11	RIBOCICLIB	17,600	\$79,825,379	\$310,221	\$80,135,600	\$4,553.16
12	VENETOCLAX	11,728	\$75,764,341	\$169,341	\$75,933,683	\$6,474.56
13	RUXOLITINIB	16,181	\$75,423,161	\$219,469	\$75,642,630	\$4,674.78
14	DURVALUMAB	8,896	\$71,410,842	\$38,179	\$71,449,022	\$8,031.59
15	PERTUZUMAB	20,472	\$64,349,979	\$138,808	\$64,488,787	\$3,150.10
16	GOSERELIN^	126,904	\$63,586,184	\$2,688,585	\$66,274,769	\$522.24
17	ABIRATERONE	17,718	\$60,750,704	\$192,626	\$60,943,329	\$3,439.63
18	BEVACIZUMAB	61,608	\$60,032,805	\$358,257	\$60,391,062	\$980.25
19	CEMIPLIMAB	7,983	\$59,595,765	\$30,987	\$59,626,752	\$7,469.22
20	OBINUTUZUMAB	11,581	\$57,712,723	\$46,647	\$57,759,370	\$4,987.43
21	ACALABRUTINIB	6,415	\$52,494,391	\$81,413	\$52,575,803	\$8,195.76
22	LEUPRORELIN^^	53,599	\$51,338,577	\$641,456	\$51,980,033	\$969.79
23	TRASTUZUMAB	60,570	\$47,346,102	\$704,411	\$48,050,513	\$793.31
24	CABOZANTINIB	4,502	\$44,745,741	\$68,414	\$44,814,155	\$9,954.28
25	DASATINIB	13,939	\$43,999,818	\$333,325	\$44,333,143	\$3,180.51

\* Total Cost includes cost to the patient and cost to the Government for PBS (S85 + S100) subsidised prescriptions.

\*\* Average Price is Total Cost divided by PBS Subsidised Prescriptions.

\*\*\* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

^ Some of the usage may be for treating other conditions.

^^ Excludes PBS items that are not for cancer treatment.

**Table 5(d): Top 25 PBS Biological Products and Medicines Sorted by Highest Government Cost, 2022-23**  
Section 85 and Section 100, excluding under co-payment prescriptions.

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
1	AFLIBERCEPT	443,012	\$476,143,532	\$6,399,432	\$482,542,964	\$1,089.23
2	PEMBROLIZUMAB	52,663	\$447,023,724	\$227,317	\$447,251,041	\$8,492.70
3	NIVOLUMAB	56,066	\$411,450,540	\$246,197	\$411,696,738	\$7,343.07
4	USTEKINUMAB	48,857	\$355,959,026	\$1,300,262	\$357,259,288	\$7,312.35
5	ADALIMUMAB	330,586	\$282,747,367	\$8,209,063	\$290,956,430	\$880.12
6	DENOSUMAB	1,083,960	\$272,776,093	\$11,636,712	\$284,412,805	\$262.38
7	DUPILUMAB	151,157	\$258,822,624	\$4,020,461	\$262,843,085	\$1,738.87
8	OCRELIZUMAB	12,437	\$212,469,344	\$370,636	\$212,839,979	\$17,113.45
9	RANIBIZUMAB	141,510	\$154,853,506	\$1,842,286	\$156,695,792	\$1,107.31
10	IPILIMUMAB	7,463	\$151,019,563	\$63,743	\$151,083,307	\$20,244.31
11	SEMAGLUTIDE	1,255,370	\$146,166,023	\$20,910,340	\$167,076,364	\$133.09
12	ATEZOLIZUMAB	18,350	\$136,087,685	\$98,320	\$136,186,005	\$7,421.58
13	DARATUMUMAB	18,759	\$135,322,802	\$258,398	\$135,581,200	\$7,227.53
14	VEDOLIZUMAB	52,249	\$130,758,629	\$1,518,153	\$132,276,782	\$2,531.66
15	GUSELKUMAB	33,022	\$124,482,254	\$869,788	\$125,352,042	\$3,796.02
16	ETANERCEPT	104,690	\$103,228,102	\$2,094,179	\$105,322,281	\$1,006.04
17	INFLIXIMAB	87,787	\$95,979,389	\$2,622,948	\$98,602,337	\$1,123.20
18	SECUKINUMAB	68,220	\$93,886,065	\$1,672,110	\$95,558,174	\$1,400.74
19	GOLIMUMAB	74,841	\$84,989,722	\$1,818,006	\$86,807,728	\$1,159.90
20	DARBEPOETIN ALFA	80,104	\$84,523,734	\$1,049,035	\$85,572,769	\$1,068.27
21	NUSINERSEN	598	\$74,737,239	\$12,761	\$74,750,000	\$125,000.00
22	RISANKIZUMAB	13,779	\$73,972,197	\$378,351	\$74,350,548	\$5,395.93
23	DURVALUMAB	8,896	\$71,410,842	\$38,179	\$71,449,022	\$8,031.59
24	INSULIN GLARGINE	328,414	\$67,393,603	\$4,399,020	\$71,792,622	\$218.60
25	INSULIN DEGLUDEC + INSULIN ASPART	186,764	\$67,274,466	\$1,981,617	\$69,256,082	\$370.82

\* Total Cost includes cost to the patient and cost to the Government for PBS (S85 + S100) subsidised prescriptions.

\*\* Average Price is Total Cost divided by PBS Subsidised Prescriptions.

\*\*\* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

PBS Expenditure and Prescriptions 2022-23

**Table 5(e): Top 50 PBS Brands, excluding Efficient Funding of Chemotherapy (EFC), Sorted by Highest Government Cost, 2022-23**  
Section 85 and Section 100, excluding under co-payment prescriptions.

Rank	Brand Name	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
1	Lagevrio®	MOLNUPIRAVIR	581,621	\$646,436,341	\$7,983,390	\$654,419,731	\$1,125.17
2	Trikafta®	ELEXACAFTOR + TEZACAFTOR + IVACAFTOR (&) IVACAFTOR	24,008	\$512,857,553	\$377,478	\$513,235,031	\$21,377.67
3	Eylea®	AFLIBERCEPT	443,011	\$476,142,599	\$6,399,432	\$482,542,031	\$1,089.23
4	Stelara®	USTEKINUMAB	48,856	\$355,951,276	\$1,300,232	\$357,251,508	\$7,312.34
5	Paxlovid®	NIRMATRELVIR (&) RITONAVIR	290,910	\$334,484,588	\$4,902,977	\$339,387,565	\$1,166.64
6	Eliquis®	APIXABAN	3,717,566	\$304,365,273	\$39,406,542	\$343,771,814	\$92.47
7	Dupilent®	DUPILUMAB	151,156	\$258,820,899	\$4,020,431	\$262,841,330	\$1,738.87
8	Prolia®	DENOSUMAB	1,020,937	\$245,090,948	\$10,708,725	\$255,799,674	\$250.55
9	Humira®	ADALIMUMAB	266,562	\$227,206,085	\$6,712,834	\$233,918,919	\$877.54
10	Ocrevus®	OCRELIZUMAB	12,437	\$212,469,344	\$370,636	\$212,839,979	\$17,113.45
11	Revlimid®	LENALIDOMIDE	41,943	\$174,543,648	\$759,660	\$175,303,308	\$4,179.56
12	Rinvoq®	UPADACITINIB	122,444	\$158,285,428	\$2,704,451	\$160,989,878	\$1,314.80
13	Lucentis®	RANIBIZUMAB	141,510	\$154,853,506	\$1,842,286	\$156,695,792	\$1,107.31
14	Maviret®	GLECAPREVIR + PIBRENTASVIR	8,375	\$148,827,628	\$212,500	\$149,040,128	\$17,795.84
15	Epclusa®	SOFOSBUVIR + VELPATASVIR	11,846	\$147,255,752	\$247,283	\$147,503,035	\$12,451.72
16	Ozempic®	SEMAGLUTIDE	1,255,360	\$146,164,878	\$20,910,156	\$167,075,034	\$133.09
17	Tagrisso®	OSIMERTINIB	18,403	\$146,147,284	\$330,734	\$146,478,018	\$7,959.46
18	Xarelto®	RIVAROXABAN	2,572,021	\$138,098,390	\$31,799,185	\$169,897,575	\$66.06
19	Ferinject®	FERRIC CARBOXYMALTOSE	498,477	\$132,180,061	\$12,338,492	\$144,518,553	\$289.92
20	Entyvio®	VEDOLIZUMAB	52,249	\$130,758,629	\$1,518,153	\$132,276,782	\$2,531.66
21	Tremfya®	GUSELKUMAB	33,022	\$124,482,254	\$869,788	\$125,352,042	\$3,796.02
22	Entresto®	SACUBITRIL + VALSARTAN	661,336	\$120,538,232	\$7,815,750	\$128,353,982	\$194.08
23	Xtandi®	ENZALUTAMIDE	34,068	\$119,709,202	\$365,786	\$120,074,988	\$3,524.57
24	Darzalex SC®	DARATUMUMAB	15,887	\$112,898,292	\$249,416	\$113,147,709	\$7,122.03
25	Biktarvy®	BICTEGRAVIR + EMTRICITABINE + TENOFOVIR ALAFENAMIDE	62,274	\$109,720,530	\$1,655,073	\$111,375,603	\$1,788.48
26	Imbruvica®	IBRUTINIB	11,966	\$108,382,328	\$147,594	\$108,529,922	\$9,069.86
27	Cosentyx®	SECUKINUMAB	68,219	\$93,884,691	\$1,672,080	\$95,556,771	\$1,400.74
28	Ibrance®	PALBOCICLIB	22,192	\$93,530,492	\$344,834	\$93,875,326	\$4,230.14
29	Vyvanse®	LISDEXAMFETAMINE	1,173,708	\$86,093,694	\$29,805,649	\$115,899,343	\$98.75
30	Simponi®	GOLIMUMAB	74,829	\$84,976,063	\$1,817,737	\$86,793,800	\$1,159.90
31	Kisqali®	RIBOCICLIB	17,600	\$79,825,379	\$310,221	\$80,135,600	\$4,553.16
32	Mavenclad®	CLADRIBINE	4,285	\$79,817,950	\$112,556	\$79,930,506	\$18,653.56
33	Jakavi®	RUXOLITINIB	16,793	\$77,953,617	\$230,818	\$78,184,435	\$4,655.78
34	Venclexta®	VENETOCLAX	11,728	\$75,764,341	\$169,341	\$75,933,683	\$6,474.56
35	Skyrizi®	RISANKIZUMAB	13,779	\$73,972,197	\$378,351	\$74,350,548	\$5,395.93
36	Aranesp®	DARBEPOETIN ALFA	65,265	\$69,770,350	\$885,835	\$70,656,186	\$1,082.60
37	Xeljanz®	TOFACITINIB	54,420	\$68,445,357	\$1,056,169	\$69,501,525	\$1,277.13
38	Jardiance®	EMPAGLIFLOZIN	1,460,828	\$67,933,981	\$19,815,751	\$87,749,731	\$60.07
39	Orkambi®	LUMACAFTOR + IVACAFTOR	3,721	\$66,248,799	\$41,618	\$66,290,417	\$17,815.22
40	Spinraza®	NUSINERSEN	598	\$65,767,239	\$12,761	\$65,780,000	\$110,000.00
41	Xolair®	OMALIZUMAB	65,457	\$65,352,647	\$1,582,315	\$66,934,962	\$1,022.58
42	Gilenya®	FINGOLIMOD	41,510	\$64,962,882	\$1,034,006	\$65,996,888	\$1,589.90
43	Soliris®	ECULIZUMAB	1,557	\$64,754,612	\$40,720	\$64,795,332	\$41,615.50
44	Ryzodeg Flextouch®	INSULIN DEGLUDEC + INSULIN ASPART	175,482	\$63,210,084	\$1,858,267	\$65,068,351	\$370.80
45	Botox®	BOTULINUM TOXIN TYPE A	105,896	\$63,068,518	\$2,796,830	\$65,865,349	\$621.98
46	Fasenra Pen®	BENRALIZUMAB	18,645	\$62,222,107	\$365,659	\$62,587,765	\$3,356.81
47	Enbrel®	ETANERCEPT	62,211	\$61,317,409	\$1,295,892	\$62,613,300	\$1,006.47
48	Zytiga®	ABIRATERONE	17,718	\$60,750,704	\$192,626	\$60,943,329	\$3,439.63
49	Ultomiris®	RAVULIZUMAB	981	\$60,602,120	\$28,021	\$60,630,140	\$61,804.42
50	Trulicity®	DULAGLUTIDE	496,463	\$58,607,532	\$7,058,941	\$65,666,474	\$132.27

\* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

\*\* Average Price is Total Cost divided by PBS Subsidised Prescriptions.

\*\*\* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

Brand information is based on manufacturer code reported in the PBS Online Claims data. Brand information is excluded when the code is missing.

PBS Expenditure and Prescriptions 2022-23

**Table 5(f): Top 50 PBS Brands (excluding EFC) Sorted by Highest Subsidised Prescriptions, 2022-23**

Section 85 and Section 100, excluding under co-payment prescriptions.

Rank	Brand Name	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
1	Eliquis®	APIXABAN	3,717,566	\$304,365,273	\$39,406,542	\$343,771,814	\$92.47
2	Xarelto®	RIVAROXABAN	2,572,021	\$138,098,390	\$31,799,185	\$169,897,575	\$66.06
3	APX-Rosuvastatin®	ROSUVASTATIN	2,354,920	\$26,302,118	\$11,108,681	\$37,410,799	\$15.89
4	Rosuvastatin Sandoz®	ROSUVASTATIN	2,282,543	\$24,298,096	\$11,918,434	\$36,216,531	\$15.87
5	APO-Atorvastatin®	ATORVASTATIN	2,187,504	\$24,424,443	\$9,641,385	\$34,065,828	\$15.57
6	Lipitor®	ATORVASTATIN	2,121,098	\$22,635,425	\$9,997,753	\$32,633,178	\$15.39
7	Atorvastatin SZ®	ATORVASTATIN	1,814,207	\$19,159,060	\$8,990,363	\$28,149,423	\$15.52
8	Zempreon CFC-Free withdose counter®	SALBUTAMOL	1,781,708	\$32,923,555	\$6,787,647	\$39,711,201	\$22.29
9	Crestor®	ROSUVASTATIN	1,730,673	\$18,543,422	\$8,725,384	\$27,268,806	\$15.76
10	Pantoprazole Sandoz®	PANTOPRAZOLE	1,591,807	\$16,195,248	\$7,585,967	\$23,781,215	\$14.94
11	Pantoprazole APOTEX®	PANTOPRAZOLE	1,544,978	\$16,420,631	\$6,696,890	\$23,117,521	\$14.96
12	Jardiance®	EMPAGLIFLOZIN	1,460,828	\$67,933,981	\$19,815,751	\$87,749,731	\$60.07
13	Somac®	PANTOPRAZOLE	1,392,198	\$15,676,994	\$6,447,566	\$22,124,560	\$15.89
14	Esopreze®	ESOMEPRAZOLE	1,331,773	\$16,638,311	\$6,397,750	\$23,036,061	\$17.30
15	APO-Esomeprazole®	ESOMEPRAZOLE	1,330,971	\$17,394,895	\$5,767,686	\$23,162,582	\$17.40
16	Ozempic®	SEMAGLUTIDE	1,255,360	\$146,164,878	\$20,910,156	\$167,075,034	\$133.09
17	Cavstat®	ROSUVASTATIN	1,215,674	\$13,692,195	\$5,612,279	\$19,304,474	\$15.88
18	Doubluts®	DUTASTERIDE + TAMSULOSIN	1,211,640	\$29,555,125	\$6,740,177	\$36,295,302	\$29.96
19	Vyvanse®	LISDEXAMFETAMINE	1,173,708	\$86,093,694	\$29,805,649	\$115,899,343	\$98.75
20	APO-Frusemide®	FUROSEMIDE	1,151,908	\$13,470,162	\$4,237,011	\$17,707,173	\$15.37
21	Nexium®	ESOMEPRAZOLE	1,149,824	\$14,879,398	\$5,312,617	\$20,192,015	\$17.56
22	Palexia SR®	TAPENTADOL	1,135,952	\$39,151,940	\$8,141,346	\$47,293,286	\$41.63
23	Sozol®	PANTOPRAZOLE	1,084,600	\$11,728,672	\$4,501,818	\$16,230,490	\$14.96
24	Forxiga®	DAPAGLIFLOZIN	1,069,446	\$46,762,619	\$14,034,250	\$60,796,869	\$56.85
25	APO-Cephalexin®	CEFALOXIN	1,046,629	\$10,809,124	\$5,157,286	\$15,966,410	\$15.26
26	Prolia®	DENOSUMAB	1,020,937	\$245,090,948	\$10,708,725	\$255,799,674	\$250.55
27	Osteomol 665 Paracetamol®	PARACETAMOL	958,340	\$15,371,377	\$3,200,119	\$18,571,496	\$19.38
28	Symbicort Turbuhaler 200/6®	BUDESONIDE + FORMOTEROL	944,671	\$20,761,680	\$19,062,483	\$39,824,163	\$42.16
29	Atorvachol®	ATORVASTATIN	916,098	\$10,217,941	\$3,988,203	\$14,206,144	\$15.51
30	APO-Sertraline®	SERTRALINE	910,132	\$9,663,927	\$4,457,646	\$14,121,573	\$15.52
31	Amlodipine Sandoz®	AMLODIPINE	881,450	\$8,561,212	\$4,360,092	\$12,921,304	\$14.66
32	Lyrica®	PREGABALIN	876,404	\$15,398,983	\$3,532,074	\$18,931,056	\$21.60
33	Xalatan®	LATANOPROST	860,842	\$10,914,090	\$3,716,477	\$14,630,567	\$17.00
34	Amlodipine APOTEX®	AMLODIPINE	835,356	\$8,454,877	\$3,785,981	\$12,240,858	\$14.65
35	Trajenta®	LINAGLIPTIN	822,799	\$41,590,344	\$7,698,324	\$49,288,667	\$59.90
36	Salpraz®	PANTOPRAZOLE	821,396	\$8,804,392	\$3,479,576	\$12,283,968	\$14.95
37	Panafcortelone®	PREDNISOLONE	817,357	\$8,920,215	\$3,630,501	\$12,550,716	\$15.36
38	Plidogrel®	CLOPIDOGREL	809,866	\$10,102,332	\$3,099,742	\$13,202,074	\$16.30
39	Janumet XR®	SITAGLIPTIN + METFORMIN	805,912	\$24,441,734	\$12,291,509	\$36,733,243	\$45.58
40	ARDIX GLICLAZIDE 60mgMR®	GLICLAZIDE	790,037	\$11,922,830	\$2,884,810	\$14,807,639	\$18.74
41	APX-Paracetamol/Codeine®	PARACETAMOL + CODEINE	780,532	\$16,590,321	\$4,060,725	\$20,651,046	\$26.46
42	Spiriva Respimat®	TIOTROPIUM	776,445	\$26,629,448	\$6,852,688	\$33,482,136	\$43.12
43	APO-Candesartan®	CANDESARTAN	741,416	\$7,981,813	\$3,583,892	\$11,565,706	\$15.60
44	APO-Irbesartan®	IRBESARTAN	740,913	\$7,888,391	\$3,427,351	\$11,315,742	\$15.27
45	APX-Mirtazapine®	MIRTAZAPINE	734,222	\$8,728,436	\$3,176,022	\$11,904,458	\$16.21
46	APO-Telmisartan®	TELMISARTAN	734,098	\$7,802,277	\$3,645,883	\$11,448,160	\$15.59
47	Lercanidipine APOTEX®	LERCANIDIPINE	730,899	\$8,237,692	\$3,062,972	\$11,300,664	\$15.46
48	Escitalopram Sandoz®	ESCITALOPRAM	713,724	\$7,005,589	\$3,902,918	\$10,908,507	\$15.28
49	Movicol®	MACROGOL-3350 + SODIUM CHLORIDE + BICARBONATE + POTASSIUM CHLORIDE	691,954	\$11,965,773	\$2,410,892	\$14,376,665	\$20.78
50	APO-Pregabalin®	PREGABALIN	691,620	\$12,065,477	\$2,592,595	\$14,658,072	\$21.19

\* Total Cost includes cost to the patient and cost to the Government for PBS (S85 + S100) subsidised prescriptions.

\*\* Average Price is Total Cost divided by PBS Subsidised Prescriptions.

\*\*\* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

Brand information is based on manufacturer code reported in the PBS Online Claims data. Brand information is excluded when the code is missing.

**Table 5(g): Biosimilar Products and Medicines (excluding EFC) Sorted by Highest Government Cost, 2022-23**  
Section 85 and Section 100, excluding under co-payment prescriptions.

Brand Name	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution ***	Total Cost*	Ave. Price**
Brenzys®	ETANERCEPT	42,460	\$41,891,861	\$797,782	\$42,689,643	\$1,005.41
Inflectra®	INFLIXIMAB	20,972	\$24,920,079	\$631,867	\$25,551,947	\$1,218.38
Hyrimoz®	ADALIMUMAB	18,581	\$16,119,018	\$450,118	\$16,569,136	\$891.72
Hadlima®	ADALIMUMAB	18,434	\$15,830,345	\$422,516	\$16,252,861	\$881.68
Remsima SC®	INFLIXIMAB	19,928	\$14,547,711	\$555,804	\$15,103,515	\$757.90
Amgevita®	ADALIMUMAB	15,661	\$13,589,408	\$355,156	\$13,944,564	\$890.40
Renflexis®	INFLIXIMAB	9,486	\$11,272,262	\$261,340	\$11,533,602	\$1,215.86
Ovaleap®	FOLLITROPIN ALFA	5,633	\$7,467,814	\$190,336	\$7,658,150	\$1,359.52
Novicrit®	EPOETIN LAMBDA	6,351	\$6,450,779	\$75,371	\$6,526,150	\$1,027.58
Riximyo®	RITUXIMAB	8,171	\$4,429,162	\$189,958	\$4,619,120	\$565.31
Bemfola®	FOLLITROPIN ALFA	1,994	\$3,075,035	\$71,352	\$3,146,387	\$1,577.93
Ristempa®	PEGFILGRASTIM	23,919	\$2,991,520	\$677,801	\$3,669,321	\$153.41
Zarzio®	FILGRASTIM	9,111	\$2,028,166	\$175,072	\$2,203,238	\$241.82
Nivestim®	FILGRASTIM	6,779	\$1,578,072	\$151,595	\$1,729,667	\$255.15
Idacio®	ADALIMUMAB	1,781	\$1,558,423	\$43,406	\$1,601,829	\$899.40
Ziextenzo®	PEGFILGRASTIM	10,176	\$1,271,090	\$241,702	\$1,512,791	\$148.66
Terrosa®	TERIPARATIDE	5,011	\$813,373	\$65,757	\$879,130	\$175.44
Pelgraz®	PEGFILGRASTIM	6,073	\$734,242	\$161,456	\$895,698	\$147.49
Truxima®	RITUXIMAB	1,264	\$654,439	\$31,447	\$685,886	\$542.63
Yuflyma®	ADALIMUMAB	268	\$191,763	\$6,340	\$198,103	\$739.19
Ruxience®	RITUXIMAB	9	\$2,397	\$251	\$2,647	\$294.16

\* Total Cost includes cost to the patient and cost to the Government for PBS (S85 + S100) subsidised prescriptions.

\*\* Average Price is Total Cost divided by PBS Subsidised Prescriptions.

\*\*\* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

Brand information is based on manufacturer code reported in the PBS Online Claims data. Brand information is excluded when the code is missing.

Biosimilars included in this report are based on [Biosimilar medicines subsidised on the Pharmaceutical Benefits Scheme | Australian Government Department of Health and Aged Care](#). Excluding the reference brand.

**Table 6(a): Top 50 PBS Medicines (by Active Ingredient) Sorted by Highest Total Prescription Volume, 2022-23**  
 Section 85 and Section 100, including Doctors' Bag and under co-payment prescriptions

Rank	Drug Name	PBS Subsidised Prescriptions	Under Co-Payment Prescriptions	Total Prescription Volume	Government Cost
1	ROSUVASTATIN	9,708,579	6,760,565	16,469,144	\$107,245,624
2	ATORVASTATIN	8,095,183	4,017,260	12,112,443	\$88,233,130
3	PANTOPRAZOLE	6,950,228	3,225,884	10,176,112	\$74,501,454
4	ESOMEPRAZOLE	5,658,543	2,571,307	8,229,850	\$73,452,010
5	PERINDOPRIL	4,189,988	2,902,084	7,092,072	\$45,709,385
6	ESCITALOPRAM	2,412,389	3,669,154	6,081,543	\$24,763,248
7	METFORMIN	3,667,491	2,225,308	5,892,799	\$44,880,772
8	SERTRALINE	2,447,807	3,239,069	5,686,876	\$25,578,323
9	CEFALEXIN	2,330,170	2,790,399	5,120,569	\$24,117,494
10	AMLODIPINE	3,208,697	1,638,359	4,847,056	\$32,297,058
11	AMOXICILLIN	1,715,435	3,102,436	4,817,871	\$17,335,998
12	TELMISARTAN	2,577,298	1,948,016	4,525,314	\$27,400,232
13	CANDESARTAN	2,502,137	1,669,871	4,172,008	\$26,806,426
14	IRBESARTAN	2,650,655	1,414,171	4,064,826	\$27,998,493
15	PREGABALIN	3,025,457	847,084	3,872,541	\$52,759,038
16	SALBUTAMOL	2,821,377	953,131	3,774,508	\$52,375,271
17	APIXABAN	3,717,593	771	3,718,364	\$304,367,581
18	VENLAFAXINE	1,832,293	1,647,502	3,479,795	\$22,703,783
19	RAMIPRIL	2,086,955	1,266,753	3,353,708	\$22,170,964
20	MIRTAZAPINE	2,344,566	972,388	3,316,954	\$27,912,105
21	AMOXICILLIN + CLAVULANIC ACID	1,357,200	1,921,566	3,278,766	\$15,651,602
22	PERINDOPRIL + AMLODIPINE	1,669,057	1,514,800	3,183,857	\$19,992,783
23	PARACETAMOL + CODEINE	1,852,937	1,247,388	3,100,325	\$39,062,219
24	OXYCODONE	1,971,434	1,064,708	3,036,142	\$47,983,175
25	AMITRIPTYLINE	1,771,636	1,036,890	2,808,526	\$20,319,158
26	ATENOLOL	1,977,502	823,740	2,801,242	\$21,374,353
27	FLUOXETINE	1,163,391	1,468,410	2,631,801	\$16,153,146
28	RIVAROXABAN	2,572,037	2,432	2,574,469	\$138,099,176
29	RABEPRAZOLE	1,682,516	883,157	2,565,673	\$18,778,882
30	PREDNISOLONE	1,343,151	1,216,977	2,560,128	\$14,835,836
31	METOPROLOL TARTRATE	1,885,583	652,945	2,538,528	\$20,250,076
32	MELOXICAM	1,334,892	1,150,062	2,484,954	\$15,089,125
33	DOXYCYCLINE	1,112,717	1,368,456	2,481,173	\$12,445,998
34	DESVENLAFAXINE	1,214,605	1,227,301	2,441,906	\$22,700,663
35	BISOPROLOL	1,740,737	631,915	2,372,652	\$25,988,612
36	LERCANIDIPINE	1,726,399	630,624	2,357,023	\$19,323,789
37	CLOPIDOGREL	1,816,990	483,140	2,300,130	\$22,402,242
38	BUDESONIDE + FORMOTEROL	2,234,152	16,543	2,250,695	\$75,341,804
39	DULOXETINE	1,295,933	886,208	2,182,141	\$18,034,985
40	DIAZEPAM	1,369,445	811,686	2,181,131	\$12,910,759
41	LEVOTHYROXINE	1,111,594	948,566	2,060,160	\$20,444,897
42	IRBESARTAN + HYDROCHLOROTHIAZIDE	1,333,321	661,200	1,994,521	\$14,821,644
43	DUTASTERIDE + TAMSULOSIN	1,734,703	209,081	1,943,784	\$41,696,359
44	SIMVASTATIN	1,508,765	432,290	1,941,055	\$15,831,340
45	PARACETAMOL	1,740,300	174,329	1,914,629	\$26,762,155
46	FLUTICASONE PROPIONATE + SALMETEROL	1,911,651	816	1,912,467	\$69,731,224
47	CELECOXIB	1,003,018	908,617	1,911,635	\$11,902,207
48	GLICLAZIDE	1,362,439	494,284	1,856,723	\$20,356,535
49	TELMISARTAN + HYDROCHLOROTHIAZIDE	1,084,100	692,120	1,776,220	\$12,516,819
50	CITALOPRAM	957,691	794,067	1,751,758	\$9,951,106

PBS Expenditure and Prescriptions 2022-23

**Table 6(b): Top 10 PBS Drugs (by Active Ingredient) per age group and patient gender, Sorted by Highest Total Prescription Volume, 2022-23**

Section 85 and Section 100, excluding Doctors' Bag and including under co-payment prescriptions.


Age-group	Medicines Name	Females			Males			
		Prescriptions			Prescriptions			
		PBS Subsidised	Under Co-Payment	Total	PBS Subsidised	Under Co-Payment	Total	
00-17 y/o	AMOXICILLIN	176,145	510,469	686,614	AMOXICILLIN	194,028	551,626	745,654
	CEFALEXIN	122,117	354,135	476,252	METHYLPHENIDATE	663,801	102,867	766,668
	FLUOXETINE	112,954	195,204	308,158	CEFALEXIN	115,280	327,062	442,342
	METHYLPHENIDATE	233,001	41,526	274,527	PREDNISOLONE SODIUM PHOSPHATE	96,079	300,838	396,917
	PREDNISOLONE SODIUM PHOSPHATE	65,516	208,193	273,709	LISDEXAMFETAMINE	331,075		331,076
	SALBUTAMOL	89,336	110,376	199,712	GUANFACINE	280,018	12	280,030
	AMOXICILLIN + CLAVULANIC ACID	51,476	145,485	196,961	SALBUTAMOL	124,978	150,574	275,552
	SERTRALINE	57,022	107,515	164,537	FLUTICASON PROPRIONATE	78,819	169,733	248,552
	FLUTICASON PROPRIONATE	51,193	110,078	161,271	AMOXICILLIN + CLAVULANIC ACID	60,066	168,334	228,400
	LEVONORGESTREL + ETHINYLESTRADIOL	43,441	113,173	156,614	FLUOXETINE	118,657	106,121	224,778
<b>Total</b>		<b>1,002,201</b>	<b>1,896,154</b>	<b>2,898,355</b>	<b>Total</b>	<b>2,062,801</b>	<b>1,877,168</b>	<b>3,939,969</b>
18-39 y/o	SERTRALINE	327,892	952,931	1,280,823	AMOXICILLIN	66,370	331,674	627,862
	ESCITALOPRAM	292,090	972,068	1,264,158	AMOXICILLIN + CLAVULANIC ACID	56,666	240,624	500,911
	LEVONORGESTREL + ETHINYLESTRADIOL	171,884	781,286	953,170	CEFALEXIN	60,034	277,129	395,733
	CEFALEXIN	167,574	541,676	709,250	DIAZEPAM	111,020	128,613	336,709
	AMOXICILLIN	165,638	508,972	674,610	ESCITALOPRAM	133,032	509,779	292,988
	FLUOXETINE	184,558	396,149	580,707	FLUOXETINE	105,156	168,114	288,404
	VENLAFAXINE	166,493	286,161	452,654	MIRTAZAPINE	120,841	153,258	282,369
	AMOXICILLIN + CLAVULANIC ACID	119,795	317,019	436,814	PANTOPRAZOLE	95,561	205,628	267,045
	PARACETAMOL + CODEINE	191,524	242,975	434,499	PARACETAMOL + CODEINE	81,802	192,307	266,602
	DESVENLAFAXINE	165,886	265,878	431,764	SERTRALINE	132,222	374,246	245,114
<b>Total</b>		<b>1,935,734</b>	<b>5,232,386</b>	<b>7,168,120</b>	<b>Total</b>	<b>962,704</b>	<b>2,581,372</b>	<b>3,503,737</b>
40-59 y/o	ROSUVASTATIN	498,119	1,036,667	1,534,786	ATORVASTATIN	394,566	1,007,114	2,105,526
	ESCITALOPRAM	335,474	974,594	1,310,068	ESCITALOPRAM	171,879	577,251	1,338,407
	PANTOPRAZOLE	502,421	701,654	1,204,075	ESOMEPRAZOLE	262,452	545,476	1,013,553
	SERTRALINE	327,672	841,698	1,169,370	METFORMIN	270,646	562,314	1,000,105
	ESOMEPRAZOLE	416,957	564,924	981,881	PANTOPRAZOLE	367,884	673,602	804,304
	VENLAFAXINE	349,866	569,800	919,666	PERINDOPRIL	245,703	792,117	786,764
	ATORVASTATIN	354,356	542,252	896,608	PERINDOPRIL + AMLODIPINE	120,918	498,028	751,866
	PERINDOPRIL	235,998	550,342	786,340	ROSUVASTATIN	453,997	1,740,674	595,542
	METFORMIN	296,708	434,476	731,184	SERTRALINE	166,222	428,025	593,496
	ESTRADIOL	129,421	584,126	713,547	TELMISARTAN	95,139	484,357	558,277
<b>Total</b>		<b>3,446,992</b>	<b>6,800,533</b>	<b>10,247,525</b>	<b>Total</b>	<b>2,549,406</b>	<b>7,308,958</b>	<b>9,547,840</b>
60+ y/o	ROSUVASTATIN	4,730,788	1,609,579	6,340,367	AMLODIPINE	1,293,577	537,447	5,985,530
	ATORVASTATIN	3,616,258	907,379	4,523,637	APIXABAN	1,766,490	264	5,028,824
	PANTOPRAZOLE	3,290,408	666,418	3,956,826	ATORVASTATIN	3,658,956	1,449,335	3,211,498
	ESOMEPRAZOLE	2,969,910	594,097	3,564,007	DUTASTERIDE + TAMUSLOSIN	1,687,998	179,797	2,619,355
	PERINDOPRIL	1,826,635	557,251	2,383,886	ESOMEPRAZOLE	1,821,487	567,973	2,353,983
	AMLODIPINE	1,644,386	391,216	2,035,602	METFORMIN	1,557,340	605,682	2,122,687
	IRBESARTAN	1,524,400	404,048	1,928,448	PANTOPRAZOLE	2,526,357	731,495	1,858,820
	TELMISARTAN	1,378,638	449,516	1,828,154	PERINDOPRIL	1,817,242	852,078	1,803,684
	CANDESARTAN	1,371,131	418,859	1,789,990	ROSUVASTATIN	3,932,941	2,164,735	1,755,586
	METFORMIN	1,392,035	343,304	1,735,339	TELMISARTAN	954,719	537,512	1,464,675
<b>Total</b>		<b>23,744,589</b>	<b>6,341,667</b>	<b>30,086,256</b>	<b>Total</b>	<b>21,017,107</b>	<b>7,626,318</b>	<b>28,204,642</b>

Approximately 1.2% of all prescriptions are excluded due to unknown patient demographic details.

Reported gender in the PBS Online Climes Data is sourced from Services Australia.

Department of Health and Aged Care does not have access to Medicare personal records.

**Figure 2: Total Government Cost by gender and age-groups in 2022-23**  
Section 85 and Section 100 excluding Doctors' Bag.




Approximately 1.2% of all prescriptions are excluded due to unknown patient demographic details.  
Reported gender in the PBS Online Climes Data is sourced from Services Australia.  
Department of Health and Aged Care does not have access to Medicare personal records.


**Figure 3: PBS Prescriptions by gender and age-groups in 2022-23**

Section 85 and Section 100 including under co-payment and excluding Doctors' Bag.

**Total PBS Prescriptions**




**Total PBS Prescriptions by Gender and Age-groups**




	00-17 y/o	18-39 y/o	40-59 y/o	60+ y/o
■ M	6,504,277	12,675,371	34,766,579	96,690,002
■ F	5,525,965	20,710,042	40,262,713	110,042,224

**PBS Subsidised Prescriptions by Gender and Age-groups**



	00-17 y/o	18-39 y/o	40-59 y/o	60+ y/o
■ M	3,409,402	5,582,020	14,998,217	75,689,654
■ F	2,368,374	8,971,583	19,067,073	92,169,365


**Under Co-payment Prescriptions by Gender and Age-groups**



	00-17 y/o	18-39 y/o	40-59 y/o	60+ y/o
■ M	3,094,875	7,093,351	19,768,362	21,000,348
■ F	3,157,591	11,738,459	21,195,640	17,872,859

**Figure 4: PBS prescriptions dispensed in a Residential Aged Care Facility (RACF), 2022-23**

Section 85 and Section 100, including Doctors' Bag and under co-payment prescriptions.



**Table 6(c): Top 10 PBS Medicines (Generic Name) sorted by Highest Government Cost, dispensed in a RACF, 2022-23**

Section 85 and Section 100, including Doctors' Bag, including under co-payment prescriptions.

Rank	Drug Name	PBS Prescriptions	Government Cost	Patient Contribution**	Total Cost*
1	MOLNUPIRAVIR	58,553	\$64,052,743	\$423,064	\$64,475,807
2	APIXABAN	227,650	\$19,487,827	\$1,512,211	\$21,000,038
3	DENOSUMAB	59,079	\$14,562,300	\$434,995	\$14,997,295
4	BUPRENORPHINE	397,947	\$11,581,697	\$1,598,094	\$13,179,791
5	LEVODOPA + CARBIDOPA	53,723	\$9,998,729	\$278,755	\$10,277,483
6	RIVAROXABAN	101,587	\$6,070,595	\$653,548	\$6,724,143
7	NIRMATRELVIR (&) RITONAVIR	5,051	\$5,583,340	\$43,424	\$5,626,763
8	PANTOPRAZOLE	492,992	\$5,497,991	\$1,965,543	\$7,463,534
9	MACROGOL-3350 + SODIUM CHLORIDE + BICARBONATE + POTASSIUM CHLORIDE	343,583	\$5,033,090	\$1,258,443	\$6,291,532
10	OXYCODONE + NALOXONE	161,034	\$5,023,432	\$643,738	\$5,667,170

\* Total Cost includes cost to the patient and cost to the Government for PBS (S85 + S100) subsidised prescriptions.

\*\* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

**Table 6(d): Top 10 PBS Drugs (Generic Name) sorted by Highest Prescriptions, dispensed in a RACF, 2022-23**

Section 85 and Section 100, including Drs Bag and under co-payment prescriptions.

Rank	Drug Name	PBS Prescriptions	Government Cost	Patient Contribution**	Total Cost*
1	PANTOPRAZOLE	492,992	\$5,497,991	\$1,965,543	\$7,463,534
2	BUPRENORPHINE	397,947	\$11,581,697	\$1,598,094	\$13,179,791
3	MACROGOL-3350 + SODIUM CHLORIDE + BICARBONATE + POTASSIUM CHLORIDE	343,583	\$5,033,090	\$1,258,443	\$6,291,532
4	PARACETAMOL	329,841	\$4,104,246	\$1,107,622	\$5,211,869
5	MIRTAZAPINE	291,683	\$3,169,838	\$1,040,734	\$4,210,572
6	ATORVASTATIN	289,106	\$3,099,035	\$1,059,647	\$4,158,682
7	FUROSEMIDE	235,826	\$2,544,938	\$832,928	\$3,377,866
8	APIXABAN	227,650	\$19,487,827	\$1,512,211	\$21,000,038
9	ROSUVASTATIN	196,160	\$2,132,392	\$718,701	\$2,851,093
10	ESOMEPRAZOLE	183,069	\$2,227,100	\$701,943	\$2,929,044

\* Total Cost includes cost to the patient and cost to the Government for PBS (S85 + S100) subsidised prescriptions.

\*\* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

PBS utilisation for RACF patients is based on claims with a patient category of either:

- R - for medicines prescribed and dispensed using a National Residential Medication Chart (NRMIC); or
- N - for all non-NRMIC prescriptions for residents in a residential aged care facility

More information at [Pharmaceutical Benefits Scheme \(PBS\) | Changes to PBS Online Claiming for Residential Aged Care Claims](#).

**Table 7: Top 50 ATC Level 2 Medicines Groups Sorted by Highest Total Prescription Volume, 2022-23**  
Section 85 and Section 100, including Doctors' Bag and under co-payment prescriptions.

Rank	ATC Level 2 Code	ATC Level 2 Group	PBS Subsidised Prescriptions	Under Co-Payment Prescriptions	Total Prescriptions
1	C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM	24,772,468	16,498,553	41,271,021
2	C10	LIPID MODIFYING AGENTS	24,556,403	13,719,494	38,275,897
3	N06	PSYCHOANALEPTICS	20,262,647	16,489,980	36,752,627
4	A02	DRUGS FOR ACID RELATED DISORDERS	16,344,426	7,628,884	23,973,310
5	J01	ANTIBACTERIALS FOR SYSTEMIC USE	9,496,949	12,406,896	21,903,845
6	N02	ANALGESICS	15,047,179	5,347,191	20,394,370
7	A10	DRUGS USED IN DIABETES	16,336,742	2,786,911	19,123,653
8	R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	12,056,679	1,609,878	13,666,557
9	B01	ANTITHROMBOTIC AGENTS	10,339,664	897,299	11,236,963
10	C07	BETA BLOCKING AGENTS	7,046,020	2,625,391	9,671,411
11	C08	CALCIUM CHANNEL BLOCKERS	6,631,531	2,910,559	9,542,090
12	S01	OPHTHALMOLOGICALS	7,486,180	1,792,237	9,278,417
13	N05	PSYCHOLEPTICS	6,808,248	1,890,963	8,699,211
14	M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS	3,373,731	3,143,258	6,516,989
15	G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	2,372,499	3,018,038	5,390,537
16	H02	CORTICOSTEROIDS FOR SYSTEMIC USE	2,204,725	2,219,377	4,424,102
17	D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS	2,340,152	1,751,966	4,092,118
18	C01	CARDIAC THERAPY	3,022,296	598,147	3,620,443
19	N03	ANTIPILEPTICS	2,642,728	809,464	3,452,192
20	C03	DIURETICS	2,539,212	619,998	3,159,210
21	C02	ANTIHYPERTENSIVES	2,294,148	692,783	2,986,931
22	G04	UROLOGICALS	2,297,058	316,335	2,613,393
23	J05	ANTIVIRALS FOR SYSTEMIC USE	1,871,399	542,524	2,413,923
24	L04	IMMUNOSUPPRESSANTS	2,206,426	156,223	2,362,649
25	M04	ANTIGOUT PREPARATIONS	1,364,724	974,782	2,339,506
26	H03	THYROID THERAPY	1,247,785	981,614	2,229,399
27	M05	DRUGS FOR TREATMENT OF BONE DISEASES	2,048,532	174,194	2,222,726
28	L01	ANTINEOPLASTIC AGENTS	2,056,114	105,025	2,161,139
29	N04	ANTI-PARKINSON DRUGS	1,502,907	177,398	1,680,305
30	A04	ANTIEMETICS AND ANTINAUSEANTS	917,241	551,176	1,468,417
31	A06	DRUGS FOR CONSTIPATION	1,379,055	88,267	1,467,322
32	B03	ANTI-ANEMIC PREPARATIONS	1,155,897	138,368	1,294,265
33	L02	ENDOCRINE THERAPY	871,142	341,156	1,212,298
34	A03	DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	739,731	363,231	1,102,962
35	S02	OTOLOGICALS	513,259	519,219	1,032,478
36	A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS	948,516	48,175	996,691
37	N07	OTHER NERVOUS SYSTEM DRUGS	510,389	5,553	515,942
38	A12	MINERAL SUPPLEMENTS	348,337	57,660	405,997
39	M03	MUSCLE RELAXANTS	329,537	66,212	395,749
40	D10	ANTI-ACNE PREPARATIONS	300,001	91,942	391,943
41	D05	ANTIPSORIATICS	300,006	32,270	332,276
42	D11	OTHER DERMATOLOGICAL PREPARATIONS	246,346	82,120	328,466
43	G02	OTHER GYNECOLOGICALS	225,550	4,927	230,477
44	A09	DIGESTIVES, INCL. ENZYMES	203,624	598	204,222
45	A11	VITAMINS	153,375	43,383	196,758
46	H01	PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES	183,289	201	183,490
47	B02	ANTHEMORRHAGICS	115,513	57,992	173,505
48	L03	IMMUNOSTIMULANTS	163,288	572	163,860
49	A01	STOMATOLOGICAL PREPARATIONS	81,966	46,608	128,574
50	V03	ALL OTHER THERAPEUTIC PRODUCTS	112,956	6,966	119,922

The Anatomical Therapeutic Chemical code (ATC) is an international classification for medicines developed by the World Health Organisation and used in the PBS Schedule and referred to as [Body Systems](#).

PBS Expenditure and Prescriptions 2022-23

**Table 8: ATC Main Groups Comparison for PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2021-22 and 2022-23**  
Section 85 and Section 100, including Doctors' Bag, excluding under co-payment prescriptions.

ATC Group Level 1	PBS Subsidised Prescriptions				Government Cost				Patient Contribution***			
	2021-22	2022-23	Prescriptions Change	Percentage Change	2021-22	2022-23	Gov Cost Change	Percentage Change	2021-22	2022-23	Patient Contribution Change	Percentage Change
ALIMENTARY TRACT AND METABOLISM	35,996,950	37,516,913	1,519,963	4.2%	\$1,207,175,579	\$1,296,602,936	\$89,427,356	7.4%	\$305,714,916	\$290,401,278	-\$15,313,638	-5.0%
BLOOD AND BLOOD FORMING ORGANS	11,072,408	11,613,508	541,100	4.9%	\$872,746,580	\$944,146,289	\$71,399,708	8.2%	\$124,343,723	\$118,833,296	-\$5,510,427	-4.4%
CARDIOVASCULAR SYSTEM	69,194,769	70,865,478	1,670,709	2.4%	\$1,127,272,186	\$1,223,235,196	\$95,963,010	8.5%	\$364,675,086	\$347,815,306	-\$16,859,780	-4.6%
DERMATOLOGICALS	3,070,149	3,282,428	212,279	6.9%	\$244,991,315	\$340,249,152	\$95,257,837	38.9%	\$33,670,915	\$36,607,477	\$2,936,562	8.7%
GENITO URINARY SYSTEM AND SEX HORMONES	4,485,312	4,895,107	409,795	9.1%	\$295,715,878	\$316,342,881	\$20,627,003	7.0%	\$43,997,839	\$49,016,951	\$5,019,112	11.4%
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	3,524,882	3,727,662	202,780	5.8%	\$189,602,875	\$176,222,036	-\$13,380,839	-7.1%	\$23,113,164	\$23,331,019	\$217,856	0.9%
ANTIINFECTIVES FOR SYSTEMIC USE	9,882,366	11,483,227	1,600,861	16.2%	\$789,774,215	\$1,721,902,288	\$932,128,073	118.0%	\$70,411,773	\$82,821,638	\$12,409,865	17.6%
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	5,045,118	5,296,970	251,852	5.0%	\$6,081,201,806	\$6,581,625,603	\$500,423,797	8.2%	\$83,545,308	\$78,210,592	-\$5,334,717	-6.4%
MUSCULO-SKELETAL SYSTEM	6,944,913	7,117,938	173,025	2.5%	\$478,867,456	\$591,461,796	\$112,594,340	23.5%	\$46,067,483	\$45,816,264	-\$251,219	-0.5%
NERVOUS SYSTEM	46,121,217	46,796,044	674,827	1.5%	\$1,319,710,852	\$1,382,969,883	\$63,259,031	4.8%	\$299,678,300	\$303,401,711	\$3,723,411	1.2%
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	59,857	70,470	10,613	17.7%	\$3,240,027	\$3,582,489	\$342,462	10.6%	\$456,596	\$617,807	\$161,211	35.3%
RESPIRATORY SYSTEM	11,772,964	12,155,196	382,232	3.2%	\$948,593,104	\$1,245,856,487	\$297,263,383	31.3%	\$150,478,197	\$140,621,573	-\$9,856,624	-6.6%
SENSORY ORGANS	7,628,560	8,014,376	385,816	5.1%	\$822,813,773	\$827,291,726	\$4,477,953	0.5%	\$42,659,647	\$43,244,119	\$584,472	1.4%
VARIOUS	188,392	184,710	-3,682	-2.0%	\$66,740,607	\$59,297,628	-\$7,442,979	-11.2%	\$3,380,082	\$2,953,281	-\$426,802	-12.6%
UNLESS OTHERWISE CLASSIFIED	97,985	89,649	-8,336	-8.5%	\$3,834,999	\$3,396,508	-\$438,490	-11.4%	\$659,269	\$581,656	-\$77,613	-11.8%
<b>TOTAL</b>	<b>215,085,842</b>	<b>223,109,676</b>	<b>8,023,834</b>	<b>3.7%</b>	<b>\$14,452,281,252</b>	<b>\$16,714,182,897</b>	<b>\$2,261,901,645</b>	<b>15.7%</b>	<b>\$1,592,852,297</b>	<b>\$1,564,273,966</b>	<b>-\$28,578,331</b>	<b>-1.8%</b>

ATC Group Level 1	Total Cost*				Average Price**			
	2021-22	2022-23	Total Cost Change	Percentage Change	2021-22	2022-23	Ave Price Change	Percentage Change
ALIMENTARY TRACT AND METABOLISM	\$1,512,890,496	\$1,587,004,214	\$74,113,718	4.9%	\$42.03	\$42.30	\$0.27	0.6%
BLOOD AND BLOOD FORMING ORGANS	\$997,090,303	\$1,062,979,585	\$65,889,281	6.6%	\$90.05	\$91.53	\$1.48	1.6%
CARDIOVASCULAR SYSTEM	\$1,491,947,272	\$1,571,050,501	\$79,103,230	5.3%	\$21.56	\$22.17	\$0.61	2.8%
DERMATOLOGICALS	\$278,662,230	\$376,856,629	\$98,194,399	35.2%	\$90.77	\$114.81	\$24.04	26.5%
GENITO URINARY SYSTEM AND SEX HORMONES	\$339,713,716	\$365,359,832	\$25,646,116	7.5%	\$75.74	\$74.64	-\$1.10	-1.5%
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	\$212,716,039	\$199,553,056	-\$13,162,983	-6.2%	\$60.35	\$53.53	-\$6.82	-11.3%
ANTIINFECTIVES FOR SYSTEMIC USE	\$860,185,988	\$1,804,723,926	\$944,537,938	109.8%	\$87.04	\$157.16	\$70.12	80.6%
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	\$6,164,747,114	\$6,659,836,194	\$495,089,080	8.0%	\$1,221.92	\$1,257.29	\$35.37	2.9%
MUSCULO-SKELETAL SYSTEM	\$524,934,939	\$637,278,060	\$112,343,121	21.4%	\$75.59	\$89.53	\$13.94	18.4%
NERVOUS SYSTEM	\$1,619,389,152	\$1,686,371,594	\$66,982,442	4.1%	\$35.11	\$36.04	\$0.93	2.6%
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	\$3,696,622	\$4,200,295	\$503,673	13.6%	\$61.76	\$59.60	-\$2.16	-3.5%
RESPIRATORY SYSTEM	\$1,099,071,301	\$1,386,478,060	\$287,406,759	26.1%	\$93.36	\$114.06	\$20.70	22.2%
SENSORY ORGANS	\$865,473,420	\$870,535,845	\$5,062,425	0.6%	\$113.45	\$108.62	-\$4.83	-4.3%
VARIOUS	\$70,120,689	\$62,250,909	-\$7,869,781	-11.2%	\$372.21	\$337.02	-\$35.19	-9.5%
UNLESS OTHERWISE CLASSIFIED	\$4,494,267	\$3,978,164	-\$516,103	-11.5%	\$45.87	\$44.37	-\$1.50	-3.3%
<b>TOTAL</b>	<b>\$16,045,133,549</b>	<b>\$18,278,456,863</b>	<b>\$2,233,323,314</b>	<b>13.9%</b>	<b>\$74.60</b>	<b>\$81.93</b>	<b>\$7.33</b>	<b>9.8%</b>


\* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

\*\* Average Price is Total Cost divided by PBS Subsidised Prescriptions.

\*\*\* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.


**Figure 5(a): Percentages of Subsidised Prescriptions by ATC main groups**

Section 85 and Section 100, including Doctors' Bag, excluding under co-payment prescriptions.



**ATC - A:** ALIMENTARY TRACT AND METABOLISM **ATC - B:** BLOOD AND BLOOD FORMING ORGANS  
**ATC - C:** CARDIOVASCULAR SYSTEM **ATC - D:** DERMATOLOGICALS  
**ATC - G:** GENITO URINARY SYSTEM AND SEX HORMONES **ATC - H:** SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS  
**ATC - J:** ANTIINFECTIVES FOR SYSTEMIC USE **ATC - L:** ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS  
**ATC - M:** MUSCULO-SKELETAL SYSTEM **ATC - N:** NERVOUS SYSTEM  
**ATC - R:** RESPIRATORY SYSTEM **ATC - S:** SENSORY ORGANS  
**Others:** **ATC - P:** ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS and **ATC - V:** VARIOUS

**Figure 5(b): Percentages of Government Cost by ATC main groups, 2022-23**  
 Section 85 and Section 100, including Doctors' Bag, excluding under co-payment prescriptions.



**ATC - A:** ALIMENTARY TRACT AND METABOLISM **ATC - B:** BLOOD AND BLOOD FORMING ORGANS  
**ATC - C:** CARDIOVASCULAR SYSTEM **ATC - D:** DERMATOLOGICALS  
**ATC - G:** GENITO URINARY SYSTEM AND SEX HORMONES **ATC - H:** SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS  
**ATC - J:** ANTIINFECTIVES FOR SYSTEMIC USE **ATC - L:** ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS  
**ATC - M:** MUSCULO-SKELETAL SYSTEM **ATC - N:** NERVOUS SYSTEM  
**ATC - R:** RESPIRATORY SYSTEM **ATC - S:** SENSORY ORGANS  
**Others:** **ATC - P:** ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS and **ATC - V:** VARIOUS

PBS Expenditure and Prescriptions 2022-23

**Table 9(a): Top 35 Medicines Sorted by Highest Change to Government Cost, 2021-22 and 2022-23**  
Section 85 and Section 100, including Doctors' Bag, excluding under co-payment prescriptions.

Rank	Drug Name	2021-22					2022-23					Government Cost Change	Government Cost Change Percentage
		PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**		
1	MOLNUPIRAVIR	60,412	\$65,402,420	\$1,065,807	\$66,468,226	\$1,100	581,630	\$646,447,181	\$7,983,553	\$654,430,734	\$1,125	\$581,044,761	888.41%
2	ELEXACAFTOR + TEZACAFTOR + IVACAFTOR (&) IVACAFTOR	3,481	\$74,359,141	\$59,418	\$74,418,559	\$21,379	24,008	\$512,857,553	\$377,478	\$513,235,031	\$21,378	\$438,498,412	589.70%
3	NIRMATRELVIR (&) RITONAVIR	9,773	\$10,616,257	\$241,473	\$10,857,730	\$1,111	290,916	\$334,491,173	\$4,903,076	\$339,394,249	\$1,167	\$323,874,917	3,050.74%
4	DUPILUMAB	92,355	\$157,764,156	\$2,882,128	\$160,646,284	\$1,739	151,157	\$258,822,624	\$4,020,461	\$262,843,085	\$1,739	\$101,058,468	64.06%
5	UPADACITINIB	73,376	\$91,923,911	\$1,767,442	\$93,691,353	\$1,277	122,466	\$158,312,784	\$2,705,066	\$161,017,850	\$1,315	\$66,388,873	72.22%
6	USTEKINUMAB	42,059	\$300,225,678	\$1,285,822	\$301,511,500	\$7,169	48,857	\$355,959,026	\$1,300,262	\$357,259,288	\$7,312	\$55,733,348	18.56%
7	SEMAGLUTIDE	858,569	\$97,000,155	\$17,197,342	\$114,197,497	\$133	1,255,370	\$146,166,023	\$20,910,340	\$167,076,364	\$133	\$49,165,868	50.69%
8	RAVULIZUMAB	296	\$18,844,775	\$10,260	\$18,855,035	\$63,699	981	\$60,602,120	\$28,021	\$60,630,140	\$61,804	\$41,757,345	221.59%
9	DARATUMUMAB	12,856	\$96,359,561	\$128,841	\$96,488,402	\$7,505	18,759	\$135,322,802	\$258,398	\$135,581,200	\$7,228	\$38,963,241	40.44%
10	APIXABAN	3,323,374	\$270,768,923	\$40,030,732	\$310,799,654	\$94	3,717,593	\$304,367,581	\$39,406,767	\$343,774,347	\$92	\$33,598,658	12.41%
11	LISDEXAMFETAMINE	782,689	\$55,776,684	\$21,475,156	\$77,251,840	\$99	1,173,716	\$86,094,302	\$29,805,831	\$115,900,133	\$99	\$30,317,618	54.36%
12	GUSELKUMAB	25,091	\$94,479,472	\$772,652	\$95,252,124	\$3,796	33,022	\$124,482,254	\$869,788	\$125,352,042	\$3,796	\$30,002,782	31.76%
13	LANADELUMAB	505	\$11,829,434	\$14,649	\$11,844,083	\$23,454	1,363	\$40,427,336	\$32,660	\$40,459,996	\$29,685	\$28,597,902	241.75%
14	VEDOLIZUMAB	37,667	\$104,143,006	\$1,272,460	\$105,415,465	\$2,799	52,249	\$130,758,629	\$1,518,153	\$132,276,782	\$2,532	\$26,515,624	25.56%
15	OSIMERTINIB	15,079	\$119,669,620	\$305,395	\$119,975,016	\$7,956	18,403	\$146,147,284	\$330,734	\$146,478,018	\$7,959	\$26,477,664	22.13%
16	ZANUBRUTINIB	31	\$270,478	\$534	\$271,012	\$8,742	3,012	\$26,359,214	\$37,209	\$26,396,424	\$8,764	\$26,088,736	9,645.43%
17	SACITUZUMAB GOVITECAN	540	\$3,321,976	\$6,151	\$3,328,127	\$6,163	4,674	\$27,989,452	\$22,289	\$28,011,741	\$5,993	\$24,667,476	742.55%
18	OFATUMUMAB	4,962	\$12,655,863	\$153,650	\$12,809,513	\$2,582	15,213	\$36,675,480	\$390,353	\$37,065,833	\$2,436	\$24,019,617	189.79%
19	NUSINERSEN	381	\$41,901,965	\$8,035	\$41,910,000	\$110,000	598	\$65,767,239	\$12,761	\$65,780,000	\$110,000	\$23,865,274	56.96%
20	RISANKIZUMAB	9,361	\$50,188,635	\$297,280	\$50,485,915	\$5,393	13,779	\$73,972,197	\$378,351	\$74,350,548	\$5,396	\$23,783,562	47.39%
21	ONASEMNOGENE ABEPARVOVEC	n/p	n/p	n/p	n/p	n/p	13	\$32,860,583	\$478	\$32,861,060	\$2,527,774	n/p	n/p
22	ACALABRUTINIB	3,752	\$30,733,709	\$52,392	\$30,786,101	\$8,205	6,415	\$52,494,391	\$81,413	\$52,575,803	\$8,196	\$21,760,682	70.80%
23	SOFOSBUVIR + VELPATASVIR	10,041	\$126,424,729	\$200,020	\$126,624,749	\$12,611	11,846	\$147,255,752	\$247,283	\$147,503,035	\$12,452	\$20,831,023	16.48%
24	FREMANEZUMAB	30,871	\$16,342,171	\$914,096	\$17,256,267	\$559	68,077	\$36,376,844	\$1,684,386	\$38,061,230	\$559	\$20,034,673	122.59%
25	PEMBROLIZUMAB	50,296	\$427,011,809	\$235,725	\$427,247,534	\$8,495	52,663	\$447,023,724	\$227,317	\$447,251,041	\$8,493	\$20,011,915	4.69%
26	DENOSUMAB	1,008,264	\$253,211,232	\$12,135,410	\$265,346,642	\$263	1,083,960	\$272,776,093	\$11,636,712	\$284,412,805	\$262	\$19,564,861	7.73%
27	FERRIC CARBOXYMALTOSSE	432,907	\$113,264,567	\$12,006,412	\$125,270,979	\$289	498,481	\$132,181,193	\$12,338,555	\$144,519,748	\$290	\$18,916,626	16.70%
28	OCRELIZUMAB	11,166	\$193,987,517	\$377,720	\$194,365,238	\$17,407	12,437	\$212,469,344	\$370,636	\$212,839,979	\$17,113	\$18,481,827	9.53%
29	AVELUMAB	3,790	\$23,843,193	\$9,585	\$23,852,778	\$6,294	6,996	\$42,215,899	\$20,944	\$42,236,843	\$6,037	\$18,372,706	77.06%
30	DAPAGLIFLOZIN	693,230	\$28,418,776	\$10,982,521	\$39,401,297	\$57	1,069,453	\$46,762,858	\$14,034,409	\$60,797,267	\$57	\$18,344,082	64.55%
31	SACUBITRIL + VALSARTAN	543,655	\$102,959,230	\$7,432,288	\$110,391,518	\$203	661,338	\$120,538,619	\$7,815,757	\$128,354,376	\$194	\$17,579,389	17.07%
32	NINTEDANIB	14,893	\$41,481,561	\$214,126	\$41,695,687	\$2,800	20,981	\$57,830,050	\$259,751	\$58,089,801	\$2,769	\$16,348,489	39.41%
33	NIVOLUMAB	51,322	\$395,631,385	\$261,383	\$395,892,768	\$7,714	56,066	\$411,450,540	\$246,197	\$411,696,738	\$7,343	\$15,819,155	4.00%
34	ABEMACICLIB	3,918	\$16,500,097	\$83,432	\$16,583,529	\$4,233	7,578	\$31,888,111	\$136,499	\$32,024,610	\$4,226	\$15,388,014	93.26%
35	DAROLUTAMIDE	2,598	\$9,084,936	\$36,111	\$9,121,046	\$3,511	6,760	\$23,649,694	\$78,966	\$23,728,660	\$3,510	\$14,564,758	160.32%

\* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

\*\* Average Price is Total Cost divided by PBS Subsidised Prescriptions.

\*\*\* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

N/p: not published due to small numbers.

PBS Expenditure and Prescriptions 2022-23

Table 9(b): Top 35 Medicines Sorted by Highest Change to Subsidised Prescription Volume, 2021-22 and 2022-23

Section 85 and Section 100, including Doctors' Bag, excluding under co-payment prescriptions.

Rank	Drug Name	2021-22					2022-23					Prescription Volume Change	Prescription Volume Change Percentage
		PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**		
1	ROSUVASTATIN	9,097,671	\$94,837,603	\$46,907,454	\$141,745,057	\$15.58	9,708,579	\$107,245,624	\$46,771,590	\$154,017,215	\$15.86	610,908	6.71%
2	MOLNUPIRAVIR	60,412	\$65,402,420	\$1,065,807	\$66,468,226	\$1,100.25	581,630	\$646,447,181	\$7,983,553	\$654,430,734	\$1,125.17	521,218	862.77%
3	SEMAGLUTIDE	858,569	\$97,000,155	\$17,197,342	\$114,197,497	\$133.01	1,255,370	\$146,166,023	\$20,910,340	\$167,076,364	\$133.09	396,801	46.22%
4	APIXABAN	3,323,374	\$270,768,923	\$40,030,732	\$310,799,654	\$93.52	3,717,593	\$304,367,581	\$39,406,767	\$343,774,347	\$92.47	394,219	11.86%
5	LISDEXAMFETAMINE	782,689	\$55,776,684	\$21,475,156	\$77,251,840	\$98.70	1,173,716	\$86,094,302	\$29,805,831	\$115,900,133	\$98.75	391,027	49.96%
6	DAPAGLIFLOZIN	693,230	\$28,418,776	\$10,982,521	\$39,401,297	\$56.84	1,069,453	\$46,762,858	\$14,034,409	\$60,797,267	\$56.85	376,223	54.27%
7	PANTOPRAZOLE	6,638,852	\$64,492,131	\$31,857,610	\$96,349,741	\$14.51	6,950,228	\$74,501,454	\$30,764,122	\$105,265,576	\$15.15	311,376	4.69%
8	NIRMATRELVIR (&) RITONAVIR	9,773	\$10,616,257	\$241,473	\$10,857,730	\$1,110.99	290,916	\$334,491,173	\$4,903,076	\$339,394,249	\$1,166.64	281,143	2,876.73%
9	AMOXICILLIN	1,458,903	\$13,797,040	\$8,135,788	\$21,932,827	\$15.03	1,715,435	\$17,335,998	\$9,516,795	\$26,852,794	\$15.65	256,532	17.58%
10	EMPAGLIFLOZIN	1,216,925	\$53,558,506	\$19,521,099	\$73,079,605	\$60.05	1,460,842	\$67,934,756	\$19,815,779	\$87,750,534	\$60.07	243,917	20.04%
11	DUTASTERIDE + TAMULOSIN	1,504,324	\$38,500,233	\$7,149,781	\$45,650,014	\$30.35	1,734,703	\$41,696,359	\$10,237,769	\$51,934,128	\$29.94	230,379	15.31%
12	METHYLPHENIDATE	954,291	\$35,199,591	\$18,441,889	\$53,641,480	\$56.21	1,136,623	\$41,321,399	\$20,913,196	\$62,234,595	\$54.75	182,332	19.11%
13	DOXYCYCLINE	932,580	\$9,128,116	\$4,587,146	\$13,715,262	\$14.71	1,112,717	\$12,445,998	\$5,124,930	\$17,570,927	\$15.79	180,137	19.32%
14	CEFALEXIN	2,173,117	\$20,578,081	\$11,425,207	\$32,003,288	\$14.73	2,330,170	\$24,117,494	\$11,913,408	\$36,030,901	\$15.46	157,053	7.23%
15	BUDESONIDE + FORMOTEROL	2,085,127	\$69,934,803	\$43,922,241	\$113,857,043	\$54.60	2,234,152	\$75,341,804	\$42,089,925	\$117,431,729	\$52.56	149,025	7.15%
16	HYALURONATE SODIUM	519,282	\$15,753,638	\$2,357,281	\$18,110,919	\$34.88	667,740	\$19,920,744	\$3,143,162	\$23,063,907	\$34.54	148,458	28.59%
17	EMPAGLIFLOZIN + METFORMIN	936,269	\$40,877,125	\$17,962,651	\$58,839,776	\$62.84	1,075,430	\$49,732,540	\$17,868,782	\$67,601,322	\$62.86	139,161	14.86%
18	TAPENTADOL	998,625	\$34,645,888	\$7,421,462	\$42,067,350	\$42.13	1,135,963	\$39,152,378	\$8,141,411	\$47,293,789	\$41.63	137,338	13.75%
19	BISOPROLOL	1,604,070	\$25,408,856	\$7,399,151	\$32,808,007	\$20.45	1,740,737	\$25,988,612	\$7,272,533	\$33,261,145	\$19.11	136,667	8.52%
20	FLUTICASON FUROATE + UMECLIDINIUM + VILANTEROL	606,108	\$49,212,257	\$5,860,665	\$55,072,922	\$90.86	740,829	\$58,914,278	\$6,908,980	\$65,823,258	\$88.85	134,721	22.23%
21	AMLODIPINE	3,075,852	\$26,340,948	\$15,292,462	\$41,633,410	\$13.54	3,208,697	\$32,297,058	\$14,736,064	\$47,033,122	\$14.66	132,845	4.32%
22	RIVAROXABAN	2,439,822	\$162,873,770	\$34,483,646	\$197,357,416	\$80.89	2,572,037	\$138,099,176	\$31,799,460	\$169,898,636	\$66.06	132,215	5.42%
23	PREDNISOLONE ACETATE + PHENYLEPHRINE	30,379	\$668,016	\$180,328	\$848,344	\$27.93	157,644	\$3,328,051	\$837,673	\$4,165,724	\$26.42	127,265	418.92%
24	ATORVASTATIN	7,973,305	\$80,705,378	\$39,726,699	\$120,432,077	\$15.10	8,095,183	\$88,233,130	\$37,229,314	\$125,462,445	\$15.50	121,878	1.53%
25	SACUBITRIL + VALSARTAN	543,655	\$102,959,230	\$7,432,288	\$110,391,518	\$203.05	661,338	\$120,538,619	\$7,815,757	\$128,354,376	\$194.08	117,683	21.65%
26	METFORMIN	3,556,489	\$41,512,396	\$16,133,398	\$57,645,794	\$16.21	3,667,491	\$44,880,772	\$14,966,583	\$59,847,354	\$16.32	111,002	3.12%
27	PARACETAMOL	1,630,060	\$24,221,922	\$6,058,165	\$30,280,088	\$18.58	1,740,300	\$26,762,155	\$5,709,842	\$32,471,997	\$18.66	110,240	6.76%
28	AMOXICILLIN + CLAVULANIC ACID	1,253,455	\$13,236,736	\$6,619,558	\$19,856,293	\$15.84	1,357,200	\$15,651,602	\$7,077,825	\$22,729,426	\$16.75	103,745	8.28%
29	LINAGLIPTIN	720,279	\$36,101,490	\$7,471,022	\$43,572,512	\$60.49	822,804	\$41,590,595	\$7,698,374	\$49,288,968	\$59.90	102,525	14.23%
30	CANDESARTAN	2,403,266	\$23,811,329	\$12,533,180	\$36,344,510	\$15.12	2,502,137	\$26,806,426	\$12,223,542	\$39,029,968	\$15.60	98,871	4.11%
31	SALBUTAMOL	2,723,687	\$47,374,696	\$11,468,771	\$58,843,467	\$21.60	2,821,377	\$52,375,271	\$10,893,912	\$63,269,183	\$22.42	97,690	3.59%
32	GUANFACINE	317,391	\$34,372,149	\$5,944,558	\$40,316,707	\$127.03	410,195	\$45,160,675	\$7,075,164	\$52,235,838	\$127.34	92,804	29.24%
33	FLECAINIDE	282,882	\$9,318,895	\$1,470,207	\$10,789,103	\$38.14	372,472	\$9,506,375	\$3,536,118	\$13,042,493	\$35.02	89,590	31.67%
34	DEXAMFETAMINE	231,881	\$5,129,798	\$2,936,751	\$8,066,549	\$34.79	316,746	\$6,126,818	\$4,842,641	\$10,969,458	\$34.63	84,865	36.60%
35	BECLOMETASONE + FORMOTEROL + GLYCOPYRRONIUM	45,080	\$3,547,518	\$429,755	\$3,977,273	\$88.23	128,353	\$9,823,989	\$1,120,230	\$10,944,220	\$85.27	83,273	184.72%

\* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

\*\* Average Price is Total Cost divided by PBS Subsidised Prescriptions.

\*\*\* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.


**Table 10(a): PBS Generic Prescriptions and Government Cost per ATC level 1, 2022-23**

Section 85 and Section 100, excluding EFC items, including under co-payment prescriptions and Doctors' Bag

ATC Level 1 Group	Total PBS Prescriptions	Total Prescriptions Generic Percentage*	Total Expenditure	Total Expenditure Generic Percentage*
ATC - A: ALIMENTARY TRACT AND METABOLISM	49,074,086	62.5%	\$1,295,711,248	28.8%
ATC - B: BLOOD AND BLOOD FORMING ORGANS	12,707,169	25.4%	\$944,150,496	4.4%
ATC - C: CARDIOVASCULAR SYSTEM	108,517,436	78.5%	\$1,223,080,304	56.9%
ATC - D: DERMATOLOGICALS	5,306,199	82.8%	\$340,122,464	18.8%
ATC - G: GENITO URINARY SYSTEM AND SEX HORMONES	8,234,034	60.5%	\$316,349,889	22.1%
ATC - H: SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	6,929,442	90.3%	\$176,222,503	44.1%
ATC - J: ANTIINFECTIVES FOR SYSTEMIC USE	24,409,580	84.6%	\$1,721,288,836	9.1%
ATC - L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	4,556,294	43.2%	\$4,587,011,151	6.4%
ATC - M: MUSCULO-SKELETAL SYSTEM	11,476,119	65.9%	\$591,456,626	9.9%
ATC - N: NERVOUS SYSTEM	71,354,620	73.5%	\$1,379,088,948	43.3%
ATC - P: ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	87,367	4.4%	\$3,582,489	1.5%
ATC - R: RESPIRATORY SYSTEM	13,743,955	32.6%	\$1,245,317,608	7.4%
ATC - S: SENSORY ORGANS	10,348,183	25.4%	\$827,271,491	3.6%
ATC - V: VARIOUS	125,169	46.7%	\$28,673,130	28.4%

\* % corresponds to the utilisation of generic medicines as a proportion of total utilisation for each ATC classification

**Total Prescriptions Generic Percentage by ATC**



**Table 10(b): PBS Generic Prescriptions and Cost percentages share by ATC level 1, 2022-23**

Section 85 and Section 100, excluding Efficient Funding of Chemotherapy items, including under co-payment prescriptions and Doctors' Bag

ATC Level 1 Group	Total Prescriptions Generic Percentage*	Total Cost Generic Percentage*
<b>ATC - A:</b> ALIMENTARY TRACT AND METABOLISM	13.7%	14.6%
<b>ATC - B:</b> BLOOD AND BLOOD FORMING ORGANS	9.2%	6.1%
<b>ATC - C:</b> CARDIOVASCULAR SYSTEM	0.9%	11.4%
<b>ATC - D:</b> DERMATOLOGICALS	< 0.1%	< 0.1%
<b>ATC - G:</b> GENITO URINARY SYSTEM AND SEX HORMONES	1.4%	1.6%
<b>ATC - H:</b> SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	38.0%	27.2%
<b>ATC - J:</b> ANTIINFECTIVES FOR SYSTEMIC USE	2.0%	2.5%
<b>ATC - L:</b> ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	2.2%	2.7%
<b>ATC - M:</b> MUSCULO-SKELETAL SYSTEM	3.4%	2.3%
<b>ATC - N:</b> NERVOUS SYSTEM	23.4%	23.3%
<b>ATC - P:</b> ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	2.0%	3.6%
<b>ATC - R:</b> RESPIRATORY SYSTEM	1.2%	1.2%
<b>ATC - S:</b> SENSORY ORGANS	2.8%	3.0%
<b>ATC - V:</b> VARIOUS	< 0.1%	0.3%
<b>Total</b>	<b>100.0%</b>	<b>100.0%</b>

\* % corresponds to the utilisation of generic medicines as a proportion of total utilisation for all ATCs

Tables 10(a) and 10(b) Excludes non-therapeutic products (ATC V04 diagnostic agents, V06 general nutrients and V07 all other non-therapeutic products)

**Table 11: PBS Prescriptions and Government Cost by Formulary, 2022-23**

Section 85 and Section 100, including under co-payment prescriptions and Doctors' Bag

Formulary Group <sup>1</sup>	PBS Subsidised Prescriptions	Under co-payment Prescriptions	Total Prescriptions	Percentage	Government Cost	Percentage
F1	30,070,517	2,842,675	32,913,192	10.0%	\$10,267,291,510	61.4%
F2	183,350,531	102,009,284	285,359,815	86.8%	\$4,685,112,526	28.0%
Combination Drugs <sup>2</sup>	9,594,555	739,887	10,334,442	3.1%	\$1,758,253,014	10.5%
Other <sup>3</sup>	94,073	19,593	113,666	0.0%	\$3,525,846	0.0%
<b>Total</b>	<b>223,109,676</b>	<b>105,611,439</b>	<b>328,721,115</b>	<b>100.0%</b>	<b>\$16,714,182,897</b>	<b>100.0%</b>

**Notes:**

1. The *National Health Act 1953* provides that listed Medicines be assigned to formularies identified as F1 or F2. Generally, F1 is intended for single brand Medicines and F2 for Medicines that have multiple brands or are in a therapeutic group with other Medicines with multiple brands. Medicines on F2 are subject to the provisions of the Act relating to statutory price reductions, price disclosure and guarantee of supply. Allocation to F1 or F2 is determined by legislative instrument.
2. Combination Medicines are not allocated to any formulary.
3. The category 'Other' includes extemporaneously prepared items.

**Table 12(a): Top 20 Responsible Persons by Total Cost, 2022-23**

Section 85 and Section 100 excluding Efficient Funding of Chemotherapy items, including Doctors' Bag and under co-payment prescriptions.

Rank	Responsible Person	Prescriptions			Government Cost	Patient Contribution***	Total Cost*	Derived Ex- Manufacturer Sales**
		PBS Subsidised	Under Co-payment	Total PBS				
1	JANSSEN-CILAG PTY LTD	1,745,758	278,166	2,023,924	\$1,128,084,452	\$23,178,832	<b>\$1,151,263,284</b>	\$991,062,415
2	NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED	5,319,695	1,853,269	7,172,964	\$1,042,580,937	\$49,139,793	<b>\$1,091,720,730</b>	\$903,143,256
3	ABBVIE PTY LTD	584,424	30,352	614,776	\$771,248,229	\$11,518,277	<b>\$782,766,506</b>	\$717,197,025
4	APOTEX PTY LTD	41,271,954	20,604,370	61,876,324	\$586,004,978	\$196,432,937	<b>\$782,437,914</b>	\$313,612,422
5	BAYER AUSTRALIA LTD	3,613,554	697,469	4,311,023	\$695,992,218	\$48,598,773	<b>\$744,590,992</b>	\$634,942,871
6	MERCK SHARP & DOHME (AUSTRALIA) PTY LTD	814,127	1,394	815,521	\$663,206,310	\$11,684,847	<b>\$674,891,157</b>	\$604,611,385
7	ASTRAZENECA PTY LTD	6,614,490	1,274,273	7,888,763	\$583,443,809	\$86,681,602	<b>\$670,125,411</b>	\$513,939,854
8	VERTEX PHARMACEUTICALS (AUSTRALIA) PTY. LTD.	29,944	-	29,944	\$626,037,786	\$453,997	<b>\$626,491,783</b>	\$591,848,024
9	ALPHAPHARM PTY LTD	28,642,262	15,608,871	44,251,133	\$448,742,122	\$138,806,823	<b>\$587,548,945</b>	\$280,917,148
10	SANDOZ PTY LTD	27,050,140	25,617,436	52,667,576	\$436,505,429	\$148,794,829	<b>\$585,300,259</b>	\$320,570,845
11	ROCHE PRODUCTS PTY LTD	644,089	31,620	675,709	\$479,875,827	\$7,066,411	<b>\$486,942,238</b>	\$402,868,936
12	SANOVI-AVENTIS AUSTRALIA PTY LTD	5,403,166	2,232,579	7,635,745	\$441,041,196	\$37,882,529	<b>\$478,923,725</b>	\$357,650,556
13	BOEHRINGER INGELHEIM PTY LTD	8,487,251	1,659,464	10,146,715	\$390,551,441	\$85,963,997	<b>\$476,515,438</b>	\$356,593,510
14	AMGEN AUSTRALIA PTY LIMITED	1,296,585	107	1,296,692	\$427,942,519	\$15,383,419	<b>\$443,325,938</b>	\$351,832,876
15	TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD.	3,277,984	582,311	3,860,295	\$367,882,371	\$50,220,230	<b>\$418,102,601</b>	\$307,178,516
16	ARROW PHARMA PTY LTD	19,264,202	8,487,625	27,751,827	\$312,944,137	\$89,202,983	<b>\$402,147,121</b>	\$181,216,753
17	BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD	3,766,869	809	3,767,678	\$359,710,214	\$40,290,115	<b>\$400,000,328</b>	\$328,869,835
18	PFIZER AUSTRALIA PTY LTD	2,408,449	1,365,350	3,773,799	\$366,337,787	\$25,458,729	<b>\$391,796,516</b>	\$345,365,265
19	NOVO NORDISK PHARMACEUTICALS PTY. LIMITED	2,418,408	238,022	2,656,430	\$331,073,773	\$35,411,793	<b>\$366,485,567</b>	\$313,545,654
20	GLAXOSMITHKLINE AUSTRALIA PTY LTD	6,147,546	885,425	7,032,971	\$274,472,440	\$66,839,219	<b>\$341,311,660</b>	\$222,171,531

\* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

\*\* Derived Ex-Manufacturer Sales is derived by subtracting the Wholesale Margin amount from the Price to Pharmacist for Dispensed Quantity (per script).

\*\*\* The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

PBS Expenditure and Prescriptions 2022-23

**Table 12(b): Top 20 Responsible Persons by PBS Subsidised Prescriptions, 2022-23**

Section 85 and Section 100 excluding Efficient Funding of Chemotherapy items, including Doctors' Bag and under co-payment prescriptions.

Rank	Responsible Person	Prescriptions			Government Cost	Patient Contribution***	Total Cost*	Derived Ex- Manufacturer Sales**
		PBS Subsidised	Under Co- payment	Total PBS				
1	APOTEX PTY LTD	41,271,954	20,604,370	61,876,324	\$586,004,978	\$196,432,937	\$782,437,914	\$313,612,422
2	ALPHAPHARM PTY LTD	28,642,262	15,608,871	44,251,133	\$448,742,122	\$138,806,823	\$587,548,945	\$280,917,148
3	SANDOZ PTY LTD	27,050,140	25,617,436	52,667,576	\$436,505,429	\$148,794,829	\$585,300,259	\$320,570,845
4	ARROW PHARMA PTY LTD	19,264,202	8,487,625	27,751,827	\$312,944,137	\$89,202,983	\$402,147,121	\$181,216,753
5	ASPEN PHARMACARE AUSTRALIA PTY LIMITED	11,043,930	7,698,823	18,742,753	\$168,068,194	\$58,061,454	\$226,129,647	\$117,863,115
6	BOEHRINGER INGELHEIM PTY LTD	8,487,251	1,659,464	10,146,715	\$390,551,441	\$85,963,997	\$476,515,438	\$356,593,510
7	ASTRAZENECA PTY LTD	6,614,490	1,274,273	7,888,763	\$583,443,809	\$86,681,602	\$670,125,411	\$513,939,854
8	GLAXOSMITHKLINE AUSTRALIA PTY LTD	6,147,546	885,425	7,032,971	\$274,472,440	\$66,839,219	\$341,311,660	\$222,171,531
9	SANOVI-AVENTIS AUSTRALIA PTY LTD	5,403,166	2,232,579	7,635,745	\$441,041,196	\$37,882,529	\$478,923,725	\$357,650,556
10	NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED	5,319,695	1,853,269	7,172,964	\$1,042,580,937	\$49,139,793	\$1,091,720,730	\$903,143,256
11	BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD	3,766,869	809	3,767,678	\$359,710,214	\$40,290,115	\$400,000,328	\$328,869,835
12	BAYER AUSTRALIA LTD	3,613,554	697,469	4,311,023	\$695,992,218	\$48,598,773	\$744,590,992	\$634,942,871
13	SERVIER LABORATORIES (AUST.) PTY. LTD.	3,581,327	2,553,201	6,134,528	\$52,803,361	\$18,430,517	\$71,233,879	\$36,311,385
14	ARROTEX PHARMACEUTICALS PTY LTD	3,325,052	693,856	4,018,908	\$111,140,563	\$32,928,706	\$144,069,269	\$96,634,878
15	TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD.	3,277,984	582,311	3,860,295	\$367,882,371	\$50,220,230	\$418,102,601	\$307,178,516
16	VIATRIS PTY LTD	2,973,775	1,352,938	4,326,713	\$76,111,157	\$15,555,488	\$91,666,645	\$61,726,456
17	MUNDIPHARMA PTY LIMITED	2,904,318	361,665	3,265,983	\$130,535,477	\$19,914,597	\$150,450,074	\$96,580,880
18	NOVO NORDISK PHARMACEUTICALS PTY. LIMITED	2,418,408	238,022	2,656,430	\$331,073,773	\$35,411,793	\$366,485,567	\$313,545,654
19	PFIZER AUSTRALIA PTY LTD	2,408,449	1,365,350	3,773,799	\$366,337,787	\$25,458,729	\$391,796,516	\$345,365,265
20	UPJOHN AUSTRALIA PTY LTD	2,230,627	1,742,074	3,972,701	\$36,618,952	\$10,873,419	\$47,492,371	\$27,491,908

\* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

\*\* Derived Ex-Manufacturer Sales is derived by subtracting the Wholesale Margin amount from the Price to Pharmacist for Dispensed Quantity (per script).

\*\*\* The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

**Table 12(c): Top 20 Responsible Persons by Total PBS Prescriptions, 2022-23**

Section 85 and Section 100 excluding Efficient Funding of Chemotherapy items, including Doctors' Bag and under co-payment prescriptions.

Rank	Responsible Person	Prescriptions			Government Cost	Patient Contribution***	Total Cost*	Derived Ex- Manufacturer Sales **
		PBS Subsidised	Under Co-payment	Total PBS				
1	APOTEX PTY LTD	41,271,954	20,604,370	<b>61,876,324</b>	\$586,004,978	\$196,432,937	\$782,437,914	\$313,612,422
2	SANDOZ PTY LTD	27,050,140	25,617,436	<b>52,667,576</b>	\$436,505,429	\$148,794,829	\$585,300,259	\$320,570,845
3	ALPHAPHARM PTY LTD	28,642,262	15,608,871	<b>44,251,133</b>	\$448,742,122	\$138,806,823	\$587,548,945	\$280,917,148
4	ARROW PHARMA PTY LTD	19,264,202	8,487,625	<b>27,751,827</b>	\$312,944,137	\$89,202,983	\$402,147,121	\$181,216,753
5	ASPEN PHARMACARE AUSTRALIA PTY LIMITED	11,043,930	7,698,823	<b>18,742,753</b>	\$168,068,194	\$58,061,454	\$226,129,647	\$117,863,115
6	BOEHRINGER INGELHEIM PTY LTD	8,487,251	1,659,464	<b>10,146,715</b>	\$390,551,441	\$85,963,997	\$476,515,438	\$356,593,510
7	ASTRAZENECA PTY LTD	6,614,490	1,274,273	<b>7,888,763</b>	\$583,443,809	\$86,681,602	\$670,125,411	\$513,939,854
8	SANOFI-AVENTIS AUSTRALIA PTY LTD	5,403,166	2,232,579	<b>7,635,745</b>	\$441,041,196	\$37,882,529	\$478,923,725	\$357,650,556
9	NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED	5,319,695	1,853,269	<b>7,172,964</b>	\$1,042,580,937	\$49,139,793	\$1,091,720,730	\$903,143,256
10	GLAXOSMITHKLINE AUSTRALIA PTY LTD	6,147,546	885,425	<b>7,032,971</b>	\$274,472,440	\$66,839,219	\$341,311,660	\$222,171,531
11	SERVIER LABORATORIES (AUST.) PTY. LTD.	3,581,327	2,553,201	<b>6,134,528</b>	\$52,803,361	\$18,430,517	\$71,233,879	\$36,311,385
12	VIATRIS PTY LTD	2,973,775	1,352,938	<b>4,326,713</b>	\$76,111,157	\$15,555,488	\$91,666,645	\$61,726,456
13	BAYER AUSTRALIA LTD	3,613,554	697,469	<b>4,311,023</b>	\$695,992,218	\$48,598,773	\$744,590,992	\$634,942,871
14	ARROTEX PHARMACEUTICALS PTY LTD	3,325,052	693,856	<b>4,018,908</b>	\$111,140,563	\$32,928,706	\$144,069,269	\$96,634,878
15	UPJOHN AUSTRALIA PTY LTD	2,230,627	1,742,074	<b>3,972,701</b>	\$36,618,952	\$10,873,419	\$47,492,371	\$27,491,908
16	TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD.	3,277,984	582,311	<b>3,860,295</b>	\$367,882,371	\$50,220,230	\$418,102,601	\$307,178,516
17	PFIZER AUSTRALIA PTY LTD	2,408,449	1,365,350	<b>3,773,799</b>	\$366,337,787	\$25,458,729	\$391,796,516	\$345,365,265
18	BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD	3,766,869	809	<b>3,767,678</b>	\$359,710,214	\$40,290,115	\$400,000,328	\$328,869,835
19	A.MENARINI AUSTRALIA PTY LIMITED	2,154,770	1,355,986	<b>3,510,756</b>	\$38,510,053	\$13,159,108	\$51,669,160	\$28,132,158
20	MUNDIPHARMA PTY LIMITED	2,904,318	361,665	<b>3,265,983</b>	\$130,535,477	\$19,914,597	\$150,450,074	\$96,580,880

\* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

\*\* Derived Ex-Manufacturer Sales is derived by subtracting the Wholesale Margin amount from the Price to Pharmacist for Dispensed Quantity (per script).

\*\*\* The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

**Table 13: Number of PBS Approved Suppliers, 30 June 2023**

Pharmacy State	Number of Community Pharmacies	Number of Private Hospitals	Number of Public Hospitals (Pharmaceutical Reforms)	Number of Dispensing Doctors
NSW	1,916	49	-	1
VIC	1,415	38	72	1
QLD	1,203	42	52	-
SA	469	11	15	1
WA	652	6	22	4
TAS	158	5	4	1
NT	42	1	6	-
ACT	80	5	-	-
<b>Total</b>	<b>5,935</b>	<b>157</b>	<b>171</b>	<b>8</b>

**Table 14(a): PBS Brand Premiums, 2022-23**

Section 85 and Section 100, excluding Doctors' Bag and including under co-payment prescriptions

	2022-23
Number of brands listed on the PBS <sup>(a)</sup>	5,256
Number of brands with a premium <sup>(a)</sup>	370
% of brands with a premium	7.0%
Average brand premium	\$5.57
Weighted average brand premium <sup>(b)</sup>	\$4.62
Brand premium range	\$0.50 to \$35.30
Prescriptions (millions) dispensed on the PBS <sup>(c)</sup>	185.8
Prescriptions (millions) dispensed with a brand premium	34.4
% of prescriptions dispensed with a brand premium	18.5%

Notes:

(a) A brand is defined as a unique combination of 'brand name' and 'form and strength' as at June 2023 PBS Schedule. Note this differs from cover page figure which includes Doctors' Bag.

(b) Weighted average brand premium is calculated by:

total premium value / total prescriptions with a premium = weighted average brand premium

(c) Includes only items where at least one brand is listed with a premium.

**Table 14(b): Electronic PBS Prescriptions, 2022-23**

Section 85 and Section 100, including under co-payment prescriptions and excluding Doctors' Bag

Prescription basis	PBS prescriptions	Percentage
Electronic Prescription	54,702,652	16.7%
Paper-based prescription	273,635,772	83.3%

**Table 15(a) PBS/RPBS prescriptions dispensed by Community Pharmacies, 2022-23**

Section 85 and Section 100, excluding Doctors' Bag and under co-payment prescriptions.

Prescription Type	Concessional		General		RPBS		Total	
	Prescriptions	%	Prescriptions	%	Prescriptions	%	Prescriptions	%
Discounted	40,815,928	21%	6,715,570	29%	910,935	13%	48,442,433	21%
Non-Discounted	155,401,252	79%	16,165,667	71%	6,055,431	87%	177,622,350	79%
<b>Total</b>	<b>196,217,180</b>	<b>100%</b>	<b>22,881,237</b>	<b>100%</b>	<b>6,966,366</b>	<b>100%</b>	<b>226,064,783</b>	<b>100%</b>

**Table 15(b) PBS/RPBS prescriptions by Discount Range dispensed by Community Pharmacies, 2022-23**

Section 85 and Section 100, excluding Doctors' Bag and under co-payment prescriptions.

Discount Range	Concessional		General		RPBS		Total	
	Prescriptions	%	Prescriptions	%	Prescriptions	%	Prescriptions	%
\$1.00	39,801,050	97.5%	6,568,623	97.8%	885,662	97.2%	47,255,335	97.5%
0.50 - < \$1.00	634,568	1.6%	73,554	1.1%	15,130	1.7%	723,252	1.5%
< 50c	171,791	0.4%	44,217	0.7%	5,193	0.6%	221,201	0.5%
Other	208,519	0.5%	29,176	0.4%	4,950	0.5%	242,645	0.5%
<b>Total</b>	<b>40,815,928</b>	<b>100.0%</b>	<b>6,715,570</b>	<b>100.0%</b>	<b>910,935</b>	<b>100.0%</b>	<b>48,442,433</b>	<b>100.0%</b>

**Table 16(a): PBS/RPBS Medicines Supplied under Continued Dispensing by ATC Level 1 and Dispensing Pharmacy State, 2022-23**

Section 85, including under co-payment medicines.

ATC Group Level 1	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	National
ALIMENTARY TRACT AND METABOLISM	13,976	9,184	4,280	1,999	3,332	1,551	76	798	35,196
ANTIINFECTIVES FOR SYSTEMIC USE	32	37	16	-	9	7	-	8	109
CARDIOVASCULAR SYSTEM	86,649	56,112	29,410	12,136	19,878	10,418	490	4,991	220,084
GENITO URINARY SYSTEM AND SEX HORMONES	2,159	1,480	1,018	460	705	633	23	211	6,689
RESPIRATORY SYSTEM	5,130	3,442	2,532	937	1,336	831	31	333	14,572
<b>Total</b>	<b>107,946</b>	<b>70,255</b>	<b>37,256</b>	<b>15,532</b>	<b>25,260</b>	<b>13,440</b>	<b>620</b>	<b>6,341</b>	<b>276,650</b>

**Table 16(b): PBS/RPBS Continued Dispensing Medicines Government Cost by ATC Level 1 and Dispensing Pharmacy State, 2022-23**

Section 85, including under co-payment medicines

ATC Group Level 1	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	National
ALIMENTARY TRACT AND METABOLISM	\$591,493	\$387,206	\$187,256	\$72,581	\$137,501	\$60,418	\$2,217	\$31,231	\$1,469,903
ANTIINFECTIVES FOR SYSTEMIC USE	\$8,632	\$10,278	\$3,467	\$-	\$592	\$2,096	\$-	\$2,198	\$27,263
CARDIOVASCULAR SYSTEM	\$771,436	\$476,327	\$263,616	\$105,832	\$174,101	\$88,292	\$2,823	\$37,217	\$1,919,645
GENITO URINARY SYSTEM AND SEX HORMONES	\$6,451	\$3,791	\$2,683	\$1,320	\$1,717	\$2,346	\$64	\$316	\$18,687
RESPIRATORY SYSTEM	\$142,588	\$95,917	\$54,465	\$19,455	\$35,228	\$20,999	\$777	\$8,711	\$378,141
<b>Total</b>	<b>\$1,520,601</b>	<b>\$973,518</b>	<b>\$511,487</b>	<b>\$199,188</b>	<b>\$349,138</b>	<b>\$174,152</b>	<b>\$5,880</b>	<b>\$79,674</b>	<b>\$3,813,639</b>

Note:

Continued Dispensing Emergency Measures implemented on 13 January 2020 and ended on 30 June 2022

Includes medicines listed under National Health (Continued Dispensing – Emergency Measures) Determination 2020, dispensed under ongoing or emergency measures.

Small cells with counts less than 6 are suppressed and removed from the total.

**Table 17: CPA Professional Pharmacy Programs Expenditure, 2022-23**

Under the Seventh CPA there were a range of professional programs and services delivered by community pharmacy and pharmacists to support the primary health care needs of consumers. The following table details the funds spent on these programs under the 7CPA in 2022-23 by relevant categories.

Program Type	Actual Expenditure
Rural Pharmacy Maintenance Allowance	\$21,375,000
Rural Pharmacy Workforce Program	\$4,875,000
Medication Management services	\$101,517,000
Medication Adherence services	\$127,219,719
Aboriginal & Torres Strait Islander programs	\$4,340,000
Pharmacy Program administration fees	\$8,280,421
<b>Programs Total</b>	<b>\$267,607,140</b>

**Notes:**

1. For the Programs administration arrangements for 2022-23 the total funding provided to the Pharmacy Programs Administrator (i.e., Australian Healthcare Associates) was \$267,607,140. Of this, \$8,280,421 (GST excl) was provided to the Pharmacy Programs Administrator for the purpose of Pharmacy Program administration fees. This means the Pharmacy Programs Administrator administration fees was 3.09% of the total funds.

2. The Electronic Prescription Fees (EPF) program expenditure is separately reported in Table 17 of the report.

3. Rural Pharmacy Workforce Program, Medication Management services, Medication Adherence Services and Aboriginal and Torres Strait Islander Programs are made up of multiple elements, as per the following tables.

Rural Pharmacy Workforce Program consists of the following elements:	Actual Expenditure
Rural Pharmacist Pre-Reg Inc Allowance Pharmacy - Intern Training Allowance	\$80,000
Emergency Locum Service	\$200,000
Undergraduate Scholarship Internship Pharmacy - Student Placement	\$675,000
Undergraduate Pharmacy-Scholarship Scheme	\$1,200,000
CPE - Continuing Professional Education Allowance	\$300,000
Pharmacy - Rural Administration Support	\$470,000
Rural Pharmacy - Mentor Scheme	\$50,000
Post Intern Incentive Allowance	\$260,000
Undergraduate Scholarship Internship - Intern Incentive Allowance	\$800,000
RPLO	\$840,000
<b>Program Total</b>	<b>\$4,875,000</b>

Medication Management services consist of the following elements:	Actual Expenditure
Diabetes Medscheck and Medscheck	\$47,017,500
Residential Medication Management Review (RMMR)	\$15,337,500
Home Medicines Review (HMR)	\$26,862,000
Quality Use of Medicines (QUM)	\$12,300,000
<b>Program Total</b>	<b>\$101,517,000</b>

Medication Adherence services consist of the following elements:	Actual Expenditure
Dose Administration Aids	\$96,277,228
Indigenous Dose Administration Aids	\$23,084,091
Staged Supply	\$7,858,400
<b>Program Total</b>	<b>\$127,219,719</b>

Aboriginal & Torres Strait Islander Programs consist of the following elements:	Actual Expenditure
Workforce (scholarships)	\$180,000
Workforce (traineeships)	\$160,000
Indigenous Health Services Pharmacy Support Program (IHSPS)	\$4,000,000
<b>Program Total</b>	<b>\$4,340,000</b>

**Table 18: Actual Costs of Major Components of CPA\*, 2022-23**

Component	Expenditure
Pharmacy remuneration	\$3,080,300,383
Wholesale remuneration	\$527,244,902
Professional programs	\$267,607,140
Community Services Obligation (CSO)	\$215,000,000
<b>Total</b>	<b>\$4,090,152,425</b>

\* The current Community Pharmacy Agreement is the 7<sup>th</sup> CPA.

**Notes:**

1. Details on how the above figures were identified are provided in the accompanying data tables. The above summary figures should be read in conjunction with the notes provided against each data table.
2. Professional programs and CSO figures are accrual based, as the data used to identify the amounts are based on SAP records, which is an accrual-based system.
3. The pharmacy remuneration figure is on a cash basis, as the data used to identify this amount was based on the Line by Line (LBL) data set Department of Health and Aged Care receives from Services Australia. It was not possible to use the SAP data (accrual basis) for this component, as SAP data does not provide the breakdown between medicine cost and pharmacy remuneration cost elements, whereas the LBL does.

**Table 19: Community Services Obligation (CSO) Expenditure, 2022-23**

Component	Expenditure
CSO funding pool	\$213,608,943
CSO admin	\$1,391,057
<b>Total</b>	<b>\$215,000,000</b>

The CSO for pharmaceutical wholesalers helps to ensure there are arrangements in place for all Australians to have access to PBS medicines, via their community pharmacy, in a timely manner.

Administration of the CSO funding pool is conducted by the Australian Healthcare Associates under contract to the Department of Health and Aged Care.

**PBS Information Line Report, 2022-23**

The PBS Information Line, established in 1990, is an Australia-wide service which gives information on all aspects of the Pharmaceutical Benefits Scheme to the general public, health professionals, consumer groups, and to other Government Departments and agencies.

During the period 1st July 2022 – 30th June 2023, the information line answered 6,895 calls. This was an increase of 28.11% from the previous financial year, where 5,382 calls were answered.

**Breakdown of calls by month:**

Month	Number of calls
Jul-22	544
Aug-22	707
Sep-22	493
Oct-22	615
Nov-22	539
Dec-22	383
Jan-23	509
Feb-23	563
Mar-23	632
Apr-23	546
May-23	653
Jun-23	711
<b>Total</b>	<b>6,895</b>

## National Diabetes Services Scheme (NDSS)

Since its establishment in 1987, Diabetes Australia (under Diabetes Australia Ltd) has assisted with the administration of the National Diabetes Services Scheme (NDSS) on behalf of the Australian Government. The current agreement runs from 1 July 2021 until 30 June 2024.

The NDSS is managed by the Department of Health and Aged Care through the Diabetes Support and CSO Section, in the Pharmacy Branch of the Technology Assessment and Access Division.

The NDSS provides registrants with access to products and services that support the self-management of diabetes at prices subsidised by the Australian Government. Products include syringes and needles, insulin pump consumables products, continuous glucose monitoring products, and blood and urine testing strips, and are available through NDSS Access Points nationally. Access Points mainly comprise community pharmacies plus a very small number of other entities, such as health centres, hospitals and aged care facilities. There are currently over 5,700 NDSS Access Points operating in Australia.

Details of registrant numbers are as follows:

Number of persons with diabetes registered with NDSS						
Year	Insulin using	% change	Non insulin using	% change	Total	% change
1990-91	57,087		12,121		69,208	
1991-92	67,693	18.58%	19,479	60.70%	87,172	25.96%
1992-93	79,010	16.72%	29,476	51.32%	108,486	24.45%
1993-94	90,962	15.13%	42,643	44.67%	133,605	23.15%
1994-95	103,263	13.52%	58,300	36.72%	161,563	20.93%
1995-96	116,275	12.60%	76,772	31.68%	193,047	19.49%
1996-97	129,076	11.01%	98,810	28.71%	227,886	18.05%
1997-98	142,484	10.39%	128,162	29.71%	270,646	18.76%
1998-99	155,943	9.45%	161,678	26.15%	317,621	17.36%
1999-2000	169,306	8.57%	202,549	25.28%	371,855	17.08%
2000-01	182,327	7.69%	246,805	21.85%	429,132	15.40%
2001-02	195,294	7.11%	298,599	20.99%	493,893	15.09%
2002-03	207,632	6.32%	353,825	18.50%	561,457	13.68%
2003-04	219,718	5.82%	409,150	15.64%	628,868	12.01%
2004-05	231,563	5.39%	466,409	13.99%	697,972	10.99%
2005-06	243,023	4.95%	525,365	12.64%	768,388	10.09%
2006-07	255,482	5.13%	588,580	12.03%	844,062	9.85%
2007-08	275,527	7.85%	622,340	5.74%	897,867	6.37%
2008-09	289,940	5.23%	577,567	-7.19%	867,507	-3.37%
2009-10	303,768	7.69%	653,570	8.65%	957,338	8.35%
2010-11	329,142	8.35%	703,575	7.65%	1,032,717	7.87%
2011-12	325,360	-1.15%	712,261	12.35%	1,037,621	0.48%
2012-13	342,349	5.22%	744,511	4.53%	1,086,860	4.75%
2013-14	356,807	4.22%	776,605	4.31%	1,133,412	4.28%

Number of persons with diabetes registered with NDSS						
Year	Insulin using	% change	Non insulin using	% change	Total	% change
2014-15	371,197	4.03%	804,983	3.65%	1,176,180	3.77%
2015-16	383,439	3.3%	827,812	2.84%	1,211,251	3%
2016-17	396,460	3.4%	859,610	3.8%	1,256,070	3.7%
2017-18	403,307	1.7%	873,632	1.6%	1,276,939	1.7%
2018-19	416,269	3.2%	892,801	2.2%	1,309,070	2.52%
2019-20	438,365	5.3%	928,492	4%	1,366,857	4.4%
2020-21	443,572	1.19%	945,903	1.88%	1,389,475	1.65%
2021-22	466,014	5.1%	988,155	4.45%	1,454,169	4.7%
2022-23	466,481	0.10%	984,619	-0.36%	1,451,100	-0.21%

### National Diabetes Services Scheme Expenditure

Total NDSS expenditure for products for the 2022-23 financial year was \$260m. From 2016-17, NDSS Registrant co-payments for subsidised products, are now returned to Consolidated Revenue.